Adverse Event,Category,Trial Id,URL,Condition,Intervention,Total affected,Total at risk,Serious/Other,Arm#,Arm Title,Arm-affected,Arm-at risk
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00036270,https://clinicaltrials.gov/show/NCT00036270,Breast_Neoplasms,exemestane_(Aromasin)|tamoxifen_+_exemestane|,1,4814,serious_events,arm0,Tamoxifen Followed by Exemestane,1,4814
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00038103,https://clinicaltrials.gov/show/NCT00038103,Breast_Neoplasms,Exemestane|Celecoxib_+_Exemestane|,2,109,serious_events,arm1,Combination (Exemestane + Celecoxib),1,56
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00038103,https://clinicaltrials.gov/show/NCT00038103,Breast_Neoplasms,Exemestane|Celecoxib_+_Exemestane|,2,109,other_events,arm1,Combination (Exemestane + Celecoxib),1,53
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00056407,https://clinicaltrials.gov/show/NCT00056407,Neoplasms_Prostate,Dutasteride|Placebo|,1,4105,serious_events,arm1,Dutasteride 0.5 mg,1,4105
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00071487,https://clinicaltrials.gov/show/NCT00071487,Lupus_Erythematosus_Systemic,Placebo|Belimumab_1_mg/kg|Belimumab_4_mg/kg|Belimumab_10_mg/kg|,1,114,serious_events,arm1,Belimumab 1 mg/kg Plus SOC,1,114
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00071799,https://clinicaltrials.gov/show/NCT00071799,Myelodysplastic_Syndromes,Azacitidine|Physician_Choice|,4,296,other_events,arm0,Azacitidine,1,175
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00071799,https://clinicaltrials.gov/show/NCT00071799,Myelodysplastic_Syndromes,Azacitidine|Physician_Choice|,4,296,other_events,arm1,Best Supportive Care Only,1,102
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00071799,https://clinicaltrials.gov/show/NCT00071799,Myelodysplastic_Syndromes,Azacitidine|Physician_Choice|,4,296,other_events,arm3,Standard Chemotherapy,2,19
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00075270,https://clinicaltrials.gov/show/NCT00075270,Neoplasms_Breast,Paclitaxel|GW572016_(Lapatinib)|,3,579,other_events,arm0,Lapatinib With Paclitaxel,2,293
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00075270,https://clinicaltrials.gov/show/NCT00075270,Neoplasms_Breast,Paclitaxel|GW572016_(Lapatinib)|,3,579,other_events,arm1,Placebo With Paclitaxel,1,286
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00075218,https://clinicaltrials.gov/show/NCT00075218,Gastrointestinal_Stromal_Tumor,Placebo|SU011248|,1,114,other_events,arm1,Placebo Double-Blind Treatment,1,114
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00076024,https://clinicaltrials.gov/show/NCT00076024,Breast_Neoplasms,Placebo|Docetaxel|AG-013736_(axitinib)|Docetaxel|,1,111,serious_events,arm1,Axitinib + Docetaxel (Phase 2 Double-blind),1,111
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00084266,https://clinicaltrials.gov/show/NCT00084266,Methicillin_Resistant_Staphylococcus_Aureus_(MRSA),linezolid_(Zyvox)|vancomycin|,2,587,other_events,arm1,Vancomycin,2,587
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00086580,https://clinicaltrials.gov/show/NCT00086580,B-Cell_Chronic_Lymphocytic_Leukemia,FluCAM_[Fludara_+_Campath]|fludarabine_phosphate|,18,493,other_events,arm0,Combination Arm (FluCAM),13,164
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00086580,https://clinicaltrials.gov/show/NCT00086580,B-Cell_Chronic_Lymphocytic_Leukemia,FluCAM_[Fludara_+_Campath]|fludarabine_phosphate|,18,493,serious_events,arm0,Combination Arm (FluCAM),1,164
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00086580,https://clinicaltrials.gov/show/NCT00086580,B-Cell_Chronic_Lymphocytic_Leukemia,FluCAM_[Fludara_+_Campath]|fludarabine_phosphate|,18,493,other_events,arm1,Fludarabine Alone,4,165
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00089791,https://clinicaltrials.gov/show/NCT00089791,Osteoporosis,placebo|Denosumab|,1,3886,serious_events,arm1,Denosumab 60 mg Q6M,1,3886
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00090233,https://clinicaltrials.gov/show/NCT00090233,Rotavirus_Infections,Rotateqä‹¢|Comparator:_Placebo|,1,34904,serious_events,arm0,RotaTeqä‹¢,1,34904
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00090259,https://clinicaltrials.gov/show/NCT00090259,Heart_Failure,Losartan_50_mg|Losartan_150_mg|,2,1913,serious_events,arm0,Losartan 50 mg,2,1913
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00092521,https://clinicaltrials.gov/show/NCT00092521,Cervical_Cancer|Genital_Warts|,V501|Comparator:_Placebo|Human_Papillomavirus_(HPV)_16_Monovalent|,18,5644,other_events,arm0,Group 1 - Base Study Quadrivalent Human Papillomavirus Vaccine,5,2673
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00092521,https://clinicaltrials.gov/show/NCT00092521,Cervical_Cancer|Genital_Warts|,V501|Comparator:_Placebo|Human_Papillomavirus_(HPV)_16_Monovalent|,18,5644,other_events,arm2,Group 3 - Base Study Placebo,10,2672
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00092521,https://clinicaltrials.gov/show/NCT00092521,Cervical_Cancer|Genital_Warts|,V501|Comparator:_Placebo|Human_Papillomavirus_(HPV)_16_Monovalent|,18,5644,other_events,arm1,Group 2 - Base Study Monovalent HPV (Type 16) Vaccine,3,299
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00092677,https://clinicaltrials.gov/show/NCT00092677,Aortic_Stenosis,ezetimibe_(+)_simvastatin|Comparator:_Placebo|,1,929,serious_events,arm1,Placebo,1,929
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00093015,https://clinicaltrials.gov/show/NCT00093015,Kidney_Disease|Diabetes_Mellitus|Anemia|,Placebo|darbepoetin_alfa|,1,2019,serious_events,arm0,Placebo,1,2019
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00097591,https://clinicaltrials.gov/show/NCT00097591,Coronary_Arteriosclerosis|Acute_Coronary_Syndromes|,Prasugrel|Clopidogrel|,5,13457,serious_events,arm1,Clopidogrel,2,6716
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00097591,https://clinicaltrials.gov/show/NCT00097591,Coronary_Arteriosclerosis|Acute_Coronary_Syndromes|,Prasugrel|Clopidogrel|,5,13457,serious_events,arm0,Prasugrel,3,6741
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00097786,https://clinicaltrials.gov/show/NCT00097786,Diabetes_Mellitus_Type_2,Valsartan_160_mg_+_nateglinide_60_mg|Valsartan_160_mg_+_nateglinide_placebo|Nateglinide_60_mg_+_valsartan_placebo|Valsartan_placebo_+_nateglinide_placebo|,3,6896,serious_events,arm0,Valsartan 160 mg od + Nateglinide 60 mg ac,1,2297
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00097786,https://clinicaltrials.gov/show/NCT00097786,Diabetes_Mellitus_Type_2,Valsartan_160_mg_+_nateglinide_60_mg|Valsartan_160_mg_+_nateglinide_placebo|Nateglinide_60_mg_+_valsartan_placebo|Valsartan_placebo_+_nateglinide_placebo|,3,6896,serious_events,arm3,Placebo,1,2316
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00097786,https://clinicaltrials.gov/show/NCT00097786,Diabetes_Mellitus_Type_2,Valsartan_160_mg_+_nateglinide_60_mg|Valsartan_160_mg_+_nateglinide_placebo|Nateglinide_60_mg_+_valsartan_placebo|Valsartan_placebo_+_nateglinide_placebo|,3,6896,serious_events,arm1,Valsartan 160 mg od + Placebo Nateglinide,1,2283
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00106353,https://clinicaltrials.gov/show/NCT00106353,Adenocarcinoma|Neoplasms|,Torisel,1,16,other_events,arm6,Rhabdomyosarcoma: Part 2,1,16
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00106535,https://clinicaltrials.gov/show/NCT00106535,Rheumatoid_Arthritis,tocilizumab_[RoActemra/Actemra]|Placebo|Methotrexate|,1,599,serious_events,arm1,All Tocilizumab 4 mg/kg + Methotrexate,1,599
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00109031,https://clinicaltrials.gov/show/NCT00109031,Cancer|Lymphoma|Leukemia|,palifermin|Total_Body_Irradiation|Cyclophosphamide|Etoposide|Placebo|,1,12,other_events,arm3,Palifermin 180 ‘_g/kg on Day ä_Í3 (D),1,12
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00109590,https://clinicaltrials.gov/show/NCT00109590,HIV_Infections,Didanosine_enteric-coated|Lopinavir/ritonavir|Nevirapine|Zidovudine|,16,339,other_events,arm0,Mother: LPV/r x 7d,1,56
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00109590,https://clinicaltrials.gov/show/NCT00109590,HIV_Infections,Didanosine_enteric-coated|Lopinavir/ritonavir|Nevirapine|Zidovudine|,16,339,other_events,arm1,Mother: no LPV/r,4,56
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00109590,https://clinicaltrials.gov/show/NCT00109590,HIV_Infections,Didanosine_enteric-coated|Lopinavir/ritonavir|Nevirapine|Zidovudine|,16,339,other_events,arm4,Infant: no LPV/r,2,57
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00109590,https://clinicaltrials.gov/show/NCT00109590,HIV_Infections,Didanosine_enteric-coated|Lopinavir/ritonavir|Nevirapine|Zidovudine|,16,339,other_events,arm3,Infant: LPV/r x 7d,3,56
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00109590,https://clinicaltrials.gov/show/NCT00109590,HIV_Infections,Didanosine_enteric-coated|Lopinavir/ritonavir|Nevirapine|Zidovudine|,16,339,other_events,arm2,Mother: LPV/r x 30d,4,57
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00109590,https://clinicaltrials.gov/show/NCT00109590,HIV_Infections,Didanosine_enteric-coated|Lopinavir/ritonavir|Nevirapine|Zidovudine|,16,339,other_events,arm5,Infant: LPV/r x 30d,2,57
DERMATITIS_ALLERGIC,Skin_and_subcutaneous_tissue_disorders,NCT00113763,https://clinicaltrials.gov/show/NCT00113763,Colorectal_Cancer|Metastases|,Best_supportive_care|Panitumumab|,1,229,serious_events,arm0,Panitumumab Plus BSC,1,229
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00120523,https://clinicaltrials.gov/show/NCT00120523,Atopic_Dermatitis,Pimecrolimus|Topical_corticosteroids|,1,1205,serious_events,arm0,Pimecrolimus,1,1205
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00124748,https://clinicaltrials.gov/show/NCT00124748,Leukemia_Myeloid_Chronic_Phase,Imatinib_mesylate,1,157,serious_events,arm0,Imatinib 400mg,1,157
Dermatitis_Allergic,Skin_and_subcutaneous_tissue_disorders,NCT00127101,https://clinicaltrials.gov/show/NCT00127101,Lymphoma,vorinostat|Comparator:_bexarotene|,1,5,other_events,arm1,Cohort 2,1,5
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00137423,https://clinicaltrials.gov/show/NCT00137423,Carcinoma_Renal_Cell_Metastasis,SU011248_(sunitinib),1,53,serious_events,arm1,PM Dose Sunitinib Malate (SU011248),1,53
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00139776,https://clinicaltrials.gov/show/NCT00139776,Osteoarthritis_Knee|Osteoarthritis_Hip|,Celecoxib|Celecoxib|,1,427,other_events,arm1,Celecoxib 200mg Intermittent Use,1,427
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00143507,https://clinicaltrials.gov/show/NCT00143507,Coronary_Disease|Ventricular_Dysfunction_Left|,Ivabradine|Placebo|,3,10907,serious_events,arm0,Ivabradine,1,5477
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00143507,https://clinicaltrials.gov/show/NCT00143507,Coronary_Disease|Ventricular_Dysfunction_Left|,Ivabradine|Placebo|,3,10907,serious_events,arm1,Placebo,2,5430
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00144781,https://clinicaltrials.gov/show/NCT00144781,Mucopolysaccharidosis_I|Hurler's_Syndrome|Hurler-Scheie_Syndrome|Scheie_Syndrome|,Aldurazyme_(Recombinant_Human_Alpha-L-Iduronidase)|Aldurazyme_(Recombinant_Human_Alpha-L-Iduronidase)|Aldurazyme_(Recombinant_Human_Alpha-L-Iduronidase)|Aldurazyme_(Recombinant_Human_Alpha-L-Iduronidase)|,1,8,other_events,arm0,Aldurazyme|Every Other|Week 1.2 mg/kg***Check Title***,1,8
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00144339,https://clinicaltrials.gov/show/NCT00144339,Pulmonary_Disease_Chronic_Obstructive,tiotropium|placebo|,2,3006,serious_events,arm0,Placebo,2,3006
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00145327,https://clinicaltrials.gov/show/NCT00145327,Osteoporosis,Zoledronic_Acid|Placebo|,1,613,serious_events,arm0,Zoledronic Acid 6,1,613
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00146770,https://clinicaltrials.gov/show/NCT00146770,Mucopolysaccharidosis_I|Hurler's_Syndrome|Hurler-Scheie_Syndrome|Scheie_Syndrome|,Aldurazyme|Aldurazyme|placebo|,1,23,other_events,arm0,Placebo/|Aldurazyme***Check Title***,1,23
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00153062,https://clinicaltrials.gov/show/NCT00153062,Stroke,Aggrenox|Aggrenox|Clopidogrel_placebo|Clopidogrel_placebo|Micardis|Micardis|Aggrenox_placebo|Aggrenox_placebo|Clopidogrel|Clopidogrel|Micardis_placebo|Micardis_placebo|,1,5023,serious_events,arm3,Clopidogrel / Placebo,1,5023
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00159861,https://clinicaltrials.gov/show/NCT00159861,Pulmonary_Hypertension,Sildenafil_citrate,1,134,other_events,arm1,Sildenafil/Sildenafil,1,134
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00160524,https://clinicaltrials.gov/show/NCT00160524,Crohn's_Disease,Certolizumab_Pegol_(CDP870),1,595,serious_events,arm0,Certolizumab Pegol,1,595
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00165646,https://clinicaltrials.gov/show/NCT00165646,Non-erosive_Gastroesophageal_Reflux_Disease,E3810|E3810|Placebo|,1,93,other_events,arm1,E3810 5 mg,1,93
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00171210,https://clinicaltrials.gov/show/NCT00171210,Transfusional_Iron_Overload_in_‘_-thalassemia,Deferasirox,1,296,serious_events,arm0,ICL670,1,296
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00170950,https://clinicaltrials.gov/show/NCT00170950,Hypertension,Benazepril/amlodipine_20/5_mg_-_Dose_Level_1_from_Day_1_to_Month_1|Benazepril/amlodipine_40/5_mg_-_Dose_Level_2_from_Month_1_to_Month_2|Benazepril/amlodipine_40/10_mg_-_Dose_Level_3_from_Month_2_to_Month_3_and_thereafter|Benazepril/hydrochlorothiazide_20/12.5_mg_-_Dose_Level_1_from_Day_1_to_Month_1|Benazepril/hydrochlorothiazide_40/12.5_mg_-_Dose_Level_2_from_Month_1_to_Month_2|Benazepril/hydrochlorothiazide_40/25_mg_-_Dose_Level_3_from_Month_2_to_Month_3_and_thereafter|,1,5740,serious_events,arm0,Benazepril / Amlodipine,1,5740
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00175877,https://clinicaltrials.gov/show/NCT00175877,Rheumatoid_Arthritis,Certolizumab_Pegol,1,846,serious_events,arm0,Certolizumab Pegol,1,846
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00191477,https://clinicaltrials.gov/show/NCT00191477,Bladder_Neoplasms,Gemcitabine|Placebo|,1,166,other_events,arm0,Gemcitabine,1,166
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00195650,https://clinicaltrials.gov/show/NCT00195650,Rheumatoid_Arthritis,Adalimumab,1,846,serious_events,arm0,Adalimumab,1,846
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00195676,https://clinicaltrials.gov/show/NCT00195676,Psoriasis,adalimumab,1,1468,serious_events,arm0,All Adalimumab Treatment,1,1468
Dermatitis_Allergic,Skin_and_subcutaneous_tissue_disorders,NCT00202878,https://clinicaltrials.gov/show/NCT00202878,Hypercholesterolemia|Myocardial_Infarction|,ezetimibe/simvastatin|simvastatin|Placebo_for_simvastatin_40_mg|Placebo_for_ezetimibe_10_mg/simvastatin_40_mg_combination|,1,9077,serious_events,arm1,Simvastatin,1,9077
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00205803,https://clinicaltrials.gov/show/NCT00205803,Healthy_Subjects|Pneumococcal_Infections|,13-Valent_Pneumococcal_Conjugate_Vaccine_(13vPnC)|7-Valent_Pneumococcal_Conjugate_Vaccine_(7vPnC)|,1,86,other_events,arm2,13vPnC Toddler Dose,1,86
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00205777,https://clinicaltrials.gov/show/NCT00205777,Osteoporosis,Bazedoxifene_Acetate|Placebo|,1,1885,serious_events,arm3,Placebo,1,1885
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00206726,https://clinicaltrials.gov/show/NCT00206726,Leukemia_Lymphocytic_Chronic_B-Cell,Alemtuzumab_plus_Fludarabine,1,57,other_events,arm0,Alemtuzumab Plus Fludarabine,1,57
Dermatitis_Allergic,Skin_and_subcutaneous_tissue_disorders,NCT00214539,https://clinicaltrials.gov/show/NCT00214539,Asthma,Bronchial_Thermoplasty_with_the_Alair_System|Control|,1,17,other_events,arm5,Control (Steroid Wean and Reduced Steroid Phases),1,17
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00219284,https://clinicaltrials.gov/show/NCT00219284,Parkinson's_Disease_With_End_of_Dose_Wearing_Off,Carbidopa/levodopa/entacapone,1,179,serious_events,arm1,Delayed Switch,1,179
Dermatitis_Allergic,Immune_system_disorders,NCT00227266,https://clinicaltrials.gov/show/NCT00227266,Spinal_Muscular_Atrophy,Valproic_Acid_and_Levocarnitine|Placebo|,6,94,other_events,arm0,Cohort 1a Sitters Placebo Then Treatment,3,31
Dermatitis_Allergic,Immune_system_disorders,NCT00227266,https://clinicaltrials.gov/show/NCT00227266,Spinal_Muscular_Atrophy,Valproic_Acid_and_Levocarnitine|Placebo|,6,94,other_events,arm1,Cohort 1b Sitters Treatment,2,30
Dermatitis_Allergic,Immune_system_disorders,NCT00227266,https://clinicaltrials.gov/show/NCT00227266,Spinal_Muscular_Atrophy,Valproic_Acid_and_Levocarnitine|Placebo|,6,94,other_events,arm2,Cohort 2 Standers and Walkers - Treatment,1,33
Dermatitis_Allergic,Skin_and_subcutaneous_tissue_disorders,NCT00229723,https://clinicaltrials.gov/show/NCT00229723,Neoplasms_Squamous_Cell,gefitinib_(Iressa)|cisplatin|radiotherapy|Gefitinib_(Iressa)|,2,31,other_events,arm3,250mg/250mg,2,31
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00232180,https://clinicaltrials.gov/show/NCT00232180,Heart_Failure,Eplerenone,2,2724,serious_events,arm0,Eplerenone: Double-blind Phase (May 25 2010 Data Cut-off),1,1360
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00232180,https://clinicaltrials.gov/show/NCT00232180,Heart_Failure,Eplerenone,2,2724,serious_events,arm2,Eplerenone: Double-blind Phase,1,1364
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00235755,https://clinicaltrials.gov/show/NCT00235755,Partial-Onset_Seizures,Retigabine|Retigabine|Placebo|,1,178,serious_events,arm4,Retigabine 300 mg TID - DB Phase (Titration Plus Maintenance),1,178
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00235716,https://clinicaltrials.gov/show/NCT00235716,Alzheimer's_Disease,dl-alpha-tocopherol|Memantine|dl-alpha-tocopherol|Memantine|Placebo|,2,307,other_events,arm1,Memantine,1,155
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00235716,https://clinicaltrials.gov/show/NCT00235716,Alzheimer's_Disease,dl-alpha-tocopherol|Memantine|dl-alpha-tocopherol|Memantine|Placebo|,2,307,other_events,arm0,Vitamin E,1,152
Dermatitis_Allergic,Skin_and_subcutaneous_tissue_disorders,NCT00240331,https://clinicaltrials.gov/show/NCT00240331,Renal_Failure,10mg_Rosuvastatin|Placebo|,1,1389,serious_events,arm0,Rosuvastatin 10mg,1,1389
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00246571,https://clinicaltrials.gov/show/NCT00246571,Breast_Neoplasms,SU011248|Chemotherapy|,2,213,other_events,arm0,Sunitinib,1,110
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00246571,https://clinicaltrials.gov/show/NCT00246571,Breast_Neoplasms,SU011248|Chemotherapy|,2,213,other_events,arm1,Standard of Care,1,103
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00249795,https://clinicaltrials.gov/show/NCT00249795,Atrial_Fibrillation|Cardiovascular_Disease|,Irbesartan|placebo|,1,4518,serious_events,arm0,Irbesartan,1,4518
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00249873,https://clinicaltrials.gov/show/NCT00249873,Atrial_Fibrillation|Vascular_Risk|,clopidogrel_(SR25990C)|placebo|,1,3772,serious_events,arm0,Clopidogrel + ASA,1,3772
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00262522,https://clinicaltrials.gov/show/NCT00262522,Human_Immunodeficiency_Virus_Infections,lopinavir/ritonavir_(LPV/r)_(tablet_or_capsule)_with_nucleoside_reverse_transcriptase_inhibitors_(NRTIs)|lopinavir/ritonavir_(LPV/r)_(tablet_or_capsule)_with_nucleoside_reverse_transcriptase_inhibitors_(NRTIs)|lopinavir/ritonavir_(LPV/r)_(tablet_or_capsule)_with_nucleoside_reverse_transcriptase_inhibitors_(NRTIs)|lopinavir/ritonavir_(LPV/r)_(tablet_or_capsule)_with_nucleoside_reverse_transcriptase_inhibitors_(NRTIs)|,1,331,serious_events,arm1,LPV/r 400/100 mg BID Tablet,1,331
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00262600,https://clinicaltrials.gov/show/NCT00262600,Atrial_Fibrillation|Stroke|,warfarin|Dabigatran_dose_1|Dabigatran_dose_2|,1,5983,serious_events,arm0,Dabigatran 110 mg,1,5983
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00267969,https://clinicaltrials.gov/show/NCT00267969,Psoriasis,ustekinumab|placebo|,1,120,serious_events,arm4,Placebo -> Ustekinumab 90 mg (After CP),1,120
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00268203,https://clinicaltrials.gov/show/NCT00268203,Lymphoma_Non-Hodgkin,Iodine_I_131_Tositumomab_Therapeutic_Regimen,1,765,other_events,arm0,Tositumomab and Iodine I-131 Tositumomab,1,765
DERMATITIS_ALLERGIC,Skin_and_subcutaneous_tissue_disorders,NCT00272779,https://clinicaltrials.gov/show/NCT00272779,HIV_Infections,ATV|RTV|Tenofovi-Emtricitabine_(TDF/FTC)_tablet|LPV|,1,437,serious_events,arm1,LPV/RTV/Tenofovir/Emtricitabine,1,437
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00273858,https://clinicaltrials.gov/show/NCT00273858,Ankylosing_Spondylitis|Arthritis_Psoriatic|Arthritis_Rheumatoid|Spondylitis_Ankylosing|,There_is_no_Intervention._The_study_is_observational.,3,1760,serious_events,arm0,Etanercept,1,880
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00273858,https://clinicaltrials.gov/show/NCT00273858,Ankylosing_Spondylitis|Arthritis_Psoriatic|Arthritis_Rheumatoid|Spondylitis_Ankylosing|,There_is_no_Intervention._The_study_is_observational.,3,1760,other_events,arm0,Etanercept,2,880
Dermatitis_Allergic,Skin_and_subcutaneous_tissue_disorders,NCT00281918,https://clinicaltrials.gov/show/NCT00281918,Leukemia,Rituximab|Cyclophosphamide|Fludarabine_Phosphate|,1,402,serious_events,arm1,Fludarabine+Cyclophosphamide+Rituximab (FCR),1,402
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00293722,https://clinicaltrials.gov/show/NCT00293722,Arthritis_Psoriatic|Psoriasis|Skin_Diseases_Papulosquamous|,Etanercept,9,1285,other_events,arm0,Participants With Psoriatic Arthritis,9,1285
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00306384,https://clinicaltrials.gov/show/NCT00306384,Diabetes_Mellitus,Alogliptin,1,527,serious_events,arm2,Rescued: Alogliptin 25 mg,1,527
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00307151,https://clinicaltrials.gov/show/NCT00307151,HIV_Infections,Lamivudine|Lopinavir/ritonavir|Nevirapine|Zidovudine|,19,451,other_events,arm3,Coh II: LPV/r,3,140
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00307151,https://clinicaltrials.gov/show/NCT00307151,HIV_Infections,Lamivudine|Lopinavir/ritonavir|Nevirapine|Zidovudine|,19,451,other_events,arm2,Coh II: NVP,12,147
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00307151,https://clinicaltrials.gov/show/NCT00307151,HIV_Infections,Lamivudine|Lopinavir/ritonavir|Nevirapine|Zidovudine|,19,451,other_events,arm0,Coh I: NVP,2,82
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00307151,https://clinicaltrials.gov/show/NCT00307151,HIV_Infections,Lamivudine|Lopinavir/ritonavir|Nevirapine|Zidovudine|,19,451,other_events,arm1,Coh I: LPV/r,2,82
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00310466,https://clinicaltrials.gov/show/NCT00310466,Allergy,Sublingual_immunotherapy|Placebo|,2,226,other_events,arm0,SLITone Birch,1,113
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00310466,https://clinicaltrials.gov/show/NCT00310466,Allergy,Sublingual_immunotherapy|Placebo|,2,226,other_events,arm1,Placebo,1,113
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00312845,https://clinicaltrials.gov/show/NCT00312845,Non-Hodgkin's_Lymphoma,Bortezomib_+_Rituximab|Rituximab|,1,339,serious_events,arm1,Rituximab,1,339
Dermatitis_Allergic,Skin_and_subcutaneous_tissue_disorders,NCT00312858,https://clinicaltrials.gov/show/NCT00312858,Hepatitis_A_Virus,Comparator:_VAQTAä‹¢_(Hepatitis_A_vaccine)|Comparator:_ProQuadä‹¢_(Measles_Mumps_Rubella_and_Varicella_vaccine)|Comparator:_Prevnarä‹¢_(Pneumococcal_7-Valent_Conjugate_vaccine)|,3,616,other_events,arm1,Arm 2: VAQTAä‹¢ Separate From ProQuadä‹¢ and Prevnarä‹¢,2,286
Dermatitis_Allergic,Skin_and_subcutaneous_tissue_disorders,NCT00312858,https://clinicaltrials.gov/show/NCT00312858,Hepatitis_A_Virus,Comparator:_VAQTAä‹¢_(Hepatitis_A_vaccine)|Comparator:_ProQuadä‹¢_(Measles_Mumps_Rubella_and_Varicella_vaccine)|Comparator:_Prevnarä‹¢_(Pneumococcal_7-Valent_Conjugate_vaccine)|,3,616,other_events,arm0,Arm 1: VAQTAä‹¢ + ProQuadä‹¢ + Prevnarä‹¢,1,330
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00313300,https://clinicaltrials.gov/show/NCT00313300,Acute_Coronary_Syndrome_(ACS),Apixaban|Apixaban|Placebo|Apixaban|,2,961,serious_events,arm7,Phase B Placebo,1,362
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00313300,https://clinicaltrials.gov/show/NCT00313300,Acute_Coronary_Syndrome_(ACS),Apixaban|Apixaban|Placebo|Apixaban|,2,961,serious_events,arm2,Phase A+B Placebo,1,599
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00313781,https://clinicaltrials.gov/show/NCT00313781,Prostatic_Neoplasms,CP-751871|docetaxel|prednisone|docetaxel|prednisone|,2,199,other_events,arm1,Docetaxel+Prednisone,1,102
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00313781,https://clinicaltrials.gov/show/NCT00313781,Prostatic_Neoplasms,CP-751871|docetaxel|prednisone|docetaxel|prednisone|,2,199,other_events,arm0,CP-751871+Docetaxel+Prednisone,1,97
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00317941,https://clinicaltrials.gov/show/NCT00317941,Relapsing-remitting_Multiple_Sclerosis,Betaferon/Betaseron|Rebif|Betaferon/Betaseron|,1,65,other_events,arm1,IFNB-1a 44 Mcg (Rebif) Via Rebiject II,1,65
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00317642,https://clinicaltrials.gov/show/NCT00317642,Acute_Myelogenous_Leukemia,clofarabine_(IV_formulation)|placebo|cytarabine|,2,477,other_events,arm0,Clofarabine (IV Formulation) and Cytarabine,1,161
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00317642,https://clinicaltrials.gov/show/NCT00317642,Acute_Myelogenous_Leukemia,clofarabine_(IV_formulation)|placebo|cytarabine|,2,477,other_events,arm2,Overall,1,316
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00321373,https://clinicaltrials.gov/show/NCT00321373,Influenza,Candidate_Influenza_Vaccine_GSK1247446A_-_2_different_formulations|FluarixTM|,1,407,serious_events,arm2,Fluarix Group,1,407
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00321711,https://clinicaltrials.gov/show/NCT00321711,MDS|Myelodysplastic_Syndromes|Thrombocytopenia|,Placebo|AMG_531_(Romiplostim)|Azacitidine|Decitabine|,1,15,other_events,arm4,Part B Romiplostim 750 Œµg,1,15
DERMATITIS_ALLERGIC,Skin_and_subcutaneous_tissue_disorders,NCT00326716,https://clinicaltrials.gov/show/NCT00326716,HIV_Infection,Atazanavir_+_Ritonavir_+_Combivir,1,20,other_events,arm2,Mother ATV 300 mg / RTV 100 mg,1,20
DERMATITIS_ALLERGIC,Skin_and_subcutaneous_tissue_disorders,NCT00327015,https://clinicaltrials.gov/show/NCT00327015,Diabetes,Saxagliptin|Saxagliptin|Metformin|Placebo|pioglitazone|,1,320,serious_events,arm3,Saxagliptin 5 mg + Metformin,1,320
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00328198,https://clinicaltrials.gov/show/NCT00328198,B-Cell_Chronic_Lymphocytic_Leukemia_(B-CLL),Alemtuzumab|Alemtuzumab|,1,86,other_events,arm0,Alemtuzumab 30mg,1,86
dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00336323,https://clinicaltrials.gov/show/NCT00336323,Diabetic_Retinopathy,Laser_Photocoagulation|Bevacizumab|Bevacizumab|Bevacizumab|Bevacizumab|,1,24,other_events,arm2,2.5 mg Injection at Baseline and 6 Weeks,1,24
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00345839,https://clinicaltrials.gov/show/NCT00345839,Secondary_Hyperparathyroidism|Chronic_Kidney_Disease|,Cinacalcet|Placebo|,1,1923,serious_events,arm0,Placebo,1,1923
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00358150,https://clinicaltrials.gov/show/NCT00358150,Gaucher_Disease_Type_1|Cerebroside_Lipidosis_Syndrome|Glucocerebrosidase_Deficiency_Disease|Glucosylceramide_Beta-Glucosidase_Deficiency_Disease|Gaucher_Disease_Non-Neuronopathic_Form|,Eliglustat_tartrate,2,32,other_events,arm2,Eliglustat All Participants,1,26
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00358150,https://clinicaltrials.gov/show/NCT00358150,Gaucher_Disease_Type_1|Cerebroside_Lipidosis_Syndrome|Glucocerebrosidase_Deficiency_Disease|Glucosylceramide_Beta-Glucosidase_Deficiency_Disease|Gaucher_Disease_Non-Neuronopathic_Form|,Eliglustat_tartrate,2,32,other_events,arm0,Eliglustat 50 mg,1,6
Dermatitis_Allergic,Skin_and_subcutaneous_tissue_disorders,NCT00358644,https://clinicaltrials.gov/show/NCT00358644,Acute_Myeloid_Leukemia,Decitabine,1,55,serious_events,arm0,Decitabine 20 mg/m2 Intravenous,1,55
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00359424,https://clinicaltrials.gov/show/NCT00359424,Stroke,IV_rt-PA_alone|endovascular_therapy|,1,434,other_events,arm0,Endovascular,1,434
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00362648,https://clinicaltrials.gov/show/NCT00362648,Vomiting|Diarrhea|Fever|,RotaTeqä‹¢_-_Rotavirus_Vaccine_Live_Oral_Pentavalent|Comparator:_Placebo|,13,301,other_events,arm5,Placebo - Kenya Safety Cohort,8,152
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00362648,https://clinicaltrials.gov/show/NCT00362648,Vomiting|Diarrhea|Fever|,RotaTeqä‹¢_-_Rotavirus_Vaccine_Live_Oral_Pentavalent|Comparator:_Placebo|,13,301,other_events,arm4,RotaTeqä‹¢ - Kenya Safety Cohort,5,149
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00364013,https://clinicaltrials.gov/show/NCT00364013,Metastatic_Colorectal_Cancer,Panitumumab|FOLFOX_regimen|,2,1169,serious_events,arm0,Panitumumab Plus FOLFOX,1,585
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00364013,https://clinicaltrials.gov/show/NCT00364013,Metastatic_Colorectal_Cancer,Panitumumab|FOLFOX_regimen|,2,1169,serious_events,arm1,FOLFOX Alone,1,584
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00366340,https://clinicaltrials.gov/show/NCT00366340,Vaccines_Pneumococcal,13-valent_pneumococcal_conjugate_vaccine|7-valent_pneumococcal_conjugate_vaccine|,2,583,other_events,arm0,13vPnC Infant Series,1,299
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00366340,https://clinicaltrials.gov/show/NCT00366340,Vaccines_Pneumococcal,13-valent_pneumococcal_conjugate_vaccine|7-valent_pneumococcal_conjugate_vaccine|,2,583,other_events,arm5,7vPnC Toddler Dose,1,284
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00366548,https://clinicaltrials.gov/show/NCT00366548,Vaccines_Pneumococcal,13_valent_pneumococcal_conjugate_vaccine_with_Polysorbate_80|13_valent_pneumococcal_conjugate_vaccine_without_Polysorbate_80|,15,1242,other_events,arm2,13vPnC + P80 Post-Infant Series,1,249
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00366548,https://clinicaltrials.gov/show/NCT00366548,Vaccines_Pneumococcal,13_valent_pneumococcal_conjugate_vaccine_with_Polysorbate_80|13_valent_pneumococcal_conjugate_vaccine_without_Polysorbate_80|,15,1242,other_events,arm1,13vPnC - P 80 Infant Series,8,250
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00366548,https://clinicaltrials.gov/show/NCT00366548,Vaccines_Pneumococcal,13_valent_pneumococcal_conjugate_vaccine_with_Polysorbate_80|13_valent_pneumococcal_conjugate_vaccine_without_Polysorbate_80|,15,1242,other_events,arm0,13vPnC + P80 Infant Series,3,249
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00366548,https://clinicaltrials.gov/show/NCT00366548,Vaccines_Pneumococcal,13_valent_pneumococcal_conjugate_vaccine_with_Polysorbate_80|13_valent_pneumococcal_conjugate_vaccine_without_Polysorbate_80|,15,1242,other_events,arm3,13vPnC - P80 Post-Infant Series,2,250
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00366548,https://clinicaltrials.gov/show/NCT00366548,Vaccines_Pneumococcal,13_valent_pneumococcal_conjugate_vaccine_with_Polysorbate_80|13_valent_pneumococcal_conjugate_vaccine_without_Polysorbate_80|,15,1242,other_events,arm5,13vPnC - P80 Toddler Dose,1,244
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00366678,https://clinicaltrials.gov/show/NCT00366678,Vaccines_Pneumococcal,13-valent_pneumococcal_conjugate_vaccine|7-valent_pneumococcal_conjugate_vaccine|Pentavac|,1,309,other_events,arm1,7vPnC Infant Series,1,309
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00373113,https://clinicaltrials.gov/show/NCT00373113,Breast_Neoplasms,Capecitabine|Sunitinib_malate|,1,240,other_events,arm1,Capecitabine,1,240
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00373256,https://clinicaltrials.gov/show/NCT00373256,Breast_Neoplasms,Sunitinib|paclitaxel|bevacizumab|paclitaxel|,3,477,other_events,arm1,Bevacizumab + Paclitaxel,2,242
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00373256,https://clinicaltrials.gov/show/NCT00373256,Breast_Neoplasms,Sunitinib|paclitaxel|bevacizumab|paclitaxel|,3,477,other_events,arm0,Sunitinib + Paclitaxel,1,235
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00373529,https://clinicaltrials.gov/show/NCT00373529,Acute_Myelogenous_Leukemia|Acute_Myeloid_Leukemia|,clofarabine,1,112,other_events,arm0,Clofarabine,1,112
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00373958,https://clinicaltrials.gov/show/NCT00373958,Vaccines_Pneumococcal,13_valent_pneumococcal_conjugate_vaccine|7vPnc_pneumococcal_conjugate_vaccine|,2,599,other_events,arm0,13vPnC Infant Series,1,332
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00373958,https://clinicaltrials.gov/show/NCT00373958,Vaccines_Pneumococcal,13_valent_pneumococcal_conjugate_vaccine|7vPnc_pneumococcal_conjugate_vaccine|,2,599,other_events,arm4,13vPnC Toddler Series,1,267
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00378560,https://clinicaltrials.gov/show/NCT00378560,HPV_Infections,Quadrivalent_Human_Papillomavirus_(Types_6_11_16_18)_Recombinant_Vaccine|Comparator:_Placebo|,3,480,other_events,arm0,V501,3,480
Dermatitis_Allergic,Skin_and_subcutaneous_tissue_disorders,NCT00379769,https://clinicaltrials.gov/show/NCT00379769,Diabetes_Mellitus_Type_2,Rosiglitazone|Sulfonylurea|Metformin|,2,1122,serious_events,arm3,MET in Addition to Background SU,2,1122
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00384059,https://clinicaltrials.gov/show/NCT00384059,Vaccines_Pneumococcal,13-valent_Pneumococcal_Conjugate_Vaccine|7vPnC|Pediacel|NeisVac-C|Menitorix|,1,130,other_events,arm4,13vPnC Toddler Series,1,130
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00389324,https://clinicaltrials.gov/show/NCT00389324,Immunologic_Deficiency_Syndrome,Immune_Globulin_Intravenous_(Human),2,32,other_events,arm2,Subcutaneous Phase,2,32
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00390806,https://clinicaltrials.gov/show/NCT00390806,Lung_Cancer_Non-Small_Cell,HYCAMTIN_oral_capsules|Radiation|,1,233,other_events,arm1,Radiation: WBRT Alone,1,233
Dermatitis_Allergic,Skin_and_subcutaneous_tissue_disorders,NCT00391872,https://clinicaltrials.gov/show/NCT00391872,Acute_Coronary_Syndrome,Ticagrelor|Clopidogrel|,7,18624,serious_events,arm0,TICAGRELOR,1,9333
Dermatitis_Allergic,Skin_and_subcutaneous_tissue_disorders,NCT00391872,https://clinicaltrials.gov/show/NCT00391872,Acute_Coronary_Syndrome,Ticagrelor|Clopidogrel|,7,18624,serious_events,arm1,CLOPIDOGREL,6,9291
DERMATITIS_ALLERGIC,Skin_and_subcutaneous_tissue_disorders,NCT00396877,https://clinicaltrials.gov/show/NCT00396877,Heart_Defects_Congenital,Clopidogrel_(SR25990)|placebo|,1,464,serious_events,arm1,Clopidogrel 0.2mg/kg/Day,1,464
Dermatitis_Allergic,Skin_and_subcutaneous_tissue_disorders,NCT00404924,https://clinicaltrials.gov/show/NCT00404924,Non-Small-Cell_Lung_Carcinoma,ZD6474_(vandetanib)|Best_Supportive_Care|,1,619,serious_events,arm0,Vandetanib,1,619
Dermatitis_Allergic,Skin_and_subcutaneous_tissue_disorders,NCT00403767,https://clinicaltrials.gov/show/NCT00403767,Atrial_Fibrillation|Stroke|Embolism|,Rivaroxaban|Warfarin|Matching_placebo_for_Rivaroxaban_arm_(Warfarin_placebo)|Matching_placebo_for_Warfarin_arm_(Rivaroxaban_placebo)|,1,7111,serious_events,arm0,Rivaroxaban,1,7111
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00407537,https://clinicaltrials.gov/show/NCT00407537,Hypertension|Hypercholesterolemia|,Amlodipine_besylate/atorvastatin_calcium_single_pill_combination,1,779,other_events,arm0,Caduet,1,779
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00413283,https://clinicaltrials.gov/show/NCT00413283,Lung_Cancer|Chemotherapy-Induced_Thrombocytopenia|Non-Small_Cell_Lung_Cancer|Cancer|Lung_Neoplasms|Oncology|Solid_Tumors|Thrombocytopenia|,Romiplostim|Placebo|Gemcitabine|Carboplatin|Cisplatin|,1,16,other_events,arm1,Romiplostim 250 Œµg,1,16
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00412984,https://clinicaltrials.gov/show/NCT00412984,Atrial_Fibrillation|Atrial_Flutter|,warfarin|apixaban|,1,9052,serious_events,arm1,Apixaban,1,9052
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00415532,https://clinicaltrials.gov/show/NCT00415532,Idiopathic_Thrombocytopenic_Purpura|Thrombocytopenia|Thrombocytopenia_in_Subjects_With_Immune_(Idiopathic)_Thrombocytopenic_Purpura_(ITP)|Thrombocytopenic_Purpura|,Medical_Standard_of_Care_for_ITP|Romiplostim|,1,73,serious_events,arm0,Standard of Care,1,73
Dermatitis_Allergic,Skin_and_subcutaneous_tissue_disorders,NCT00420212,https://clinicaltrials.gov/show/NCT00420212,Relapsing-Remitting_Multiple_Sclerosis,BG00012|Placebo|,1,408,serious_events,arm0,Placebo,1,408
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00420303,https://clinicaltrials.gov/show/NCT00420303,Spondylarthropathies_Enthesitis,Etanercept|Placebo|,1,12,other_events,arm1,Placebo,1,12
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00420927,https://clinicaltrials.gov/show/NCT00420927,Rheumatoid_Arthritis,adalimumab|methotrexate|placebo|,1,259,serious_events,arm2,ADA+MTX/OL ADA+MTX (Arm 3),1,259
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00421889,https://clinicaltrials.gov/show/NCT00421889,Ovarian_Cancer|Epithelial_Ovarian_Cancer|Fallopian_Tube_Cancer|Bladder_Cancer|,belinostat|Paclitaxel|Carboplatin|,1,15,other_events,arm3,Part D: Bladder Cancer MTD (N=15),1,15
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00423891,https://clinicaltrials.gov/show/NCT00423891,Hepatitis_B_Chronic,Entecavir,1,5,other_events,arm2,Nucleoside/Tide Analog (NA) - Experienced (Group C),1,5
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00426660,https://clinicaltrials.gov/show/NCT00426660,Advanced_HIV_Infection,maraviroc,1,1032,serious_events,arm0,Maraviroc,1,1032
Dermatitis_allergic,Respiratory_thoracic_and_mediastinal_disorders,NCT00427895,https://clinicaltrials.gov/show/NCT00427895,Pneumococcal_Infections,13-valent_pneumococcal_conjugate_vaccine_(13vPnC)|23-valent_Pneumococcal_Polysaccharide_Vaccine_(23vPS)|13-valent_pneumococcal_conjugate_vaccine_(13vPnC)|13-valent_pneumococcal_conjugate_vaccine_(13vPnC)|13-valent_pneumococcal_conjugate_vaccine_(13vPnC)|23-valent_Pneumococcal_Polysaccharide_Vaccine_(23vPS)|13-valent_pneumococcal_conjugate_vaccine_(13vPnC)|,1,899,other_events,arm14,13vPnC Cohort 3,1,899
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00432159,https://clinicaltrials.gov/show/NCT00432159,Cervical_Degenerative_Disc_Disease,Cervical_TDR|ACDF_with_plate|,2,166,other_events,arm1,1-level ACDF With Plate,2,166
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00434954,https://clinicaltrials.gov/show/NCT00434954,Type_2_Diabetes_Mellitus,exenatide_twice_daily_(BID)|premixed_insulin_aspart_twice_daily_(BID)|,1,247,serious_events,arm0,Exenatide Twice Daily,1,247
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00435409,https://clinicaltrials.gov/show/NCT00435409,Breast_Neoplasms,Sunitinib_+_Capecitabine|Capecitabine|,3,215,other_events,arm1,Capecitabine,3,215
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00438451,https://clinicaltrials.gov/show/NCT00438451,Focal_Epilepsy,Levetiracetam|Carbamazepine|Lamotrigine|,1,121,serious_events,arm1,Carbamazepine,1,121
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00444457,https://clinicaltrials.gov/show/NCT00444457,Vaccines_Pneumococcal,13-valent_Pneumococcal_Conjugate_Vaccine|7vPnC|,3,1454,other_events,arm6,Toddler Dose Combined 13vPnC,2,1210
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00444457,https://clinicaltrials.gov/show/NCT00444457,Vaccines_Pneumococcal,13-valent_Pneumococcal_Conjugate_Vaccine|7vPnC|,3,1454,other_events,arm3,Infant Series 7vPnC,1,244
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00452452,https://clinicaltrials.gov/show/NCT00452452,Pneumococcal_Infections,13-valent_Pneumococcal_Conjugate_Vaccine,3,202,other_events,arm1,13vPnC 12 to <24 Months of Age,1,112
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00452452,https://clinicaltrials.gov/show/NCT00452452,Pneumococcal_Infections,13-valent_Pneumococcal_Conjugate_Vaccine,3,202,other_events,arm0,13vPnC 7 to <12 Months of Age,2,90
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00459316,https://clinicaltrials.gov/show/NCT00459316,HIV_Infections|Meningitis|,Quadrivalent_meningococcal_conjugate_vaccine,3,166,other_events,arm2,Group 2,2,39
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00459316,https://clinicaltrials.gov/show/NCT00459316,HIV_Infections|Meningitis|,Quadrivalent_meningococcal_conjugate_vaccine,3,166,other_events,arm0,Group 1 (15<CD4%ä__25),1,127
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00461097,https://clinicaltrials.gov/show/NCT00461097,Hypersensitivity|Immediate_Hypersensitivity|Food_Hypersensitivity|,Egg_oral_immunotherapy|Control_Group|,3,76,other_events,arm0,Egg Oral Immunotherapy (OIT) 0-2 Years,1,40
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00461097,https://clinicaltrials.gov/show/NCT00461097,Hypersensitivity|Immediate_Hypersensitivity|Food_Hypersensitivity|,Egg_oral_immunotherapy|Control_Group|,3,76,other_events,arm2,Egg Oral Immunotherapy (OIT) 2-4 Years,2,36
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00464945,https://clinicaltrials.gov/show/NCT00464945,Pneumococcal_Vaccines,13-valent_Pneumococcal_Conjugate_Vaccine,3,265,other_events,arm3,13vPnC Pilot Post-Infant Series,2,134
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00464945,https://clinicaltrials.gov/show/NCT00464945,Pneumococcal_Vaccines,13-valent_Pneumococcal_Conjugate_Vaccine,3,265,other_events,arm4,13vPnC Manufacturing Toddler Series,1,131
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00466947,https://clinicaltrials.gov/show/NCT00466947,Pneumonia_&_AOM_Caused_by_S._Pneumoniae_&_H._Influenzae,Pneumococcal_conjugate_vaccine_GSK1024850A|Havrix|Engerix-B|Infanrix_hexa|GSK_Biologicals'_DTPa-IPV/Hib_vaccine|,362,30811,serious_events,arm1,Control Group,1,11799
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00466947,https://clinicaltrials.gov/show/NCT00466947,Pneumonia_&_AOM_Caused_by_S._Pneumoniae_&_H._Influenzae,Pneumococcal_conjugate_vaccine_GSK1024850A|Havrix|Engerix-B|Infanrix_hexa|GSK_Biologicals'_DTPa-IPV/Hib_vaccine|,362,30811,serious_events,arm0,Synflorix Group,2,11798
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00466947,https://clinicaltrials.gov/show/NCT00466947,Pneumonia_&_AOM_Caused_by_S._Pneumoniae_&_H._Influenzae,Pneumococcal_conjugate_vaccine_GSK1024850A|Havrix|Engerix-B|Infanrix_hexa|GSK_Biologicals'_DTPa-IPV/Hib_vaccine|,362,30811,other_events,arm0,Synflorix Group,163,3602
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00466947,https://clinicaltrials.gov/show/NCT00466947,Pneumonia_&_AOM_Caused_by_S._Pneumoniae_&_H._Influenzae,Pneumococcal_conjugate_vaccine_GSK1024850A|Havrix|Engerix-B|Infanrix_hexa|GSK_Biologicals'_DTPa-IPV/Hib_vaccine|,362,30811,other_events,arm1,Control Group,196,3612
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00471146,https://clinicaltrials.gov/show/NCT00471146,Carcinoma_Pancreatic_Ductal,AG-013736|Gemcitabine|Gemcitabine|placebo|,1,304,other_events,arm0,Axitinib + Gemcitabine,1,304
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00475670,https://clinicaltrials.gov/show/NCT00475670,Breast_Cancer,Trastuzumab|Taxane_(docetaxel_or_paclitaxel)|,3,41,other_events,arm1,Trastuzumab Taxane,3,41
Dermatitis_Allergic,Skin_and_subcutaneous_tissue_disorders,NCT00475852,https://clinicaltrials.gov/show/NCT00475852,Heart_Decompensation,Nesiritide|Placebo|,1,3509,other_events,arm1,Placebo,1,3509
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00478231,https://clinicaltrials.gov/show/NCT00478231,Acquired_Immunodeficiency_Syndrome|HIV_Infection|,Maraviroc,1,206,other_events,arm0,Maraviroc,1,206
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00479388,https://clinicaltrials.gov/show/NCT00479388,Primary_Hypercholesterolemia|Mixed_Dyslipidemia|,Comparator:_simvastatin|niacin_(+)_laropiprant|Comparator:_atorvastatin_calcium|,1,602,other_events,arm0,ER Niacin/Laropiprant + Run-in Statin,1,602
Dermatitis_Allergic,Skin_and_subcutaneous_tissue_disorders,NCT00485173,https://clinicaltrials.gov/show/NCT00485173,Degenerative_Disc_Disease,INFUSEŒ¬_Bone_Graft/PEEK_Spacer/Anterior_Cervical_Plate,1,224,other_events,arm0,INFUSEŒ¬ Bone Graft,1,224
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00485264,https://clinicaltrials.gov/show/NCT00485264,HIV_Infections,Raltegravir_poloxamer_film_coated_tablet|Raltegravir_chewable_tablet|Raltegravir_oral_granules_for_suspension_(20_mg/mL)|Raltegravir_poloxamer_film_coated_tablet|,4,79,other_events,arm0,Cohort I,3,59
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00485264,https://clinicaltrials.gov/show/NCT00485264,HIV_Infections,Raltegravir_poloxamer_film_coated_tablet|Raltegravir_chewable_tablet|Raltegravir_oral_granules_for_suspension_(20_mg/mL)|Raltegravir_poloxamer_film_coated_tablet|,4,79,other_events,arm3,Cohort III,1,20
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00488488,https://clinicaltrials.gov/show/NCT00488488,Infection,tigecycline,1,1025,serious_events,arm0,Tygacil,1,1025
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00488475,https://clinicaltrials.gov/show/NCT00488475,Rheumatoid_Arthritis,etanercept,28,9742,serious_events,arm0,Etanercept,3,4871
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00488475,https://clinicaltrials.gov/show/NCT00488475,Rheumatoid_Arthritis,etanercept,28,9742,other_events,arm0,Etanercept,25,4871
Dermatitis_Allergic,Skin_and_subcutaneous_tissue_disorders,NCT00488631,https://clinicaltrials.gov/show/NCT00488631,Colitis_Ulcerative,Placebo|Golimumab_50_mg|Golimumab_100_mg|Golimumab_200_mg|,9,659,other_events,arm5,GLM-I-Rsp-Golimumab 100 mg Maintenance-Golimumab 200 mg,1,14
Dermatitis_Allergic,Skin_and_subcutaneous_tissue_disorders,NCT00488631,https://clinicaltrials.gov/show/NCT00488631,Colitis_Ulcerative,Placebo|Golimumab_50_mg|Golimumab_100_mg|Golimumab_200_mg|,9,659,serious_events,arm0,Golimumab Induction Responders (GLM-I-Rsp)-Placebo Maintenance,1,156
Dermatitis_Allergic,Skin_and_subcutaneous_tissue_disorders,NCT00488631,https://clinicaltrials.gov/show/NCT00488631,Colitis_Ulcerative,Placebo|Golimumab_50_mg|Golimumab_100_mg|Golimumab_200_mg|,9,659,other_events,arm0,Golimumab Induction Responders (GLM-I-Rsp)-Placebo Maintenance,4,156
Dermatitis_Allergic,Skin_and_subcutaneous_tissue_disorders,NCT00488631,https://clinicaltrials.gov/show/NCT00488631,Colitis_Ulcerative,Placebo|Golimumab_50_mg|Golimumab_100_mg|Golimumab_200_mg|,9,659,other_events,arm1,GLM-I-Rsp-Golimumab 50 mg Maintenance,1,154
Dermatitis_Allergic,Skin_and_subcutaneous_tissue_disorders,NCT00488631,https://clinicaltrials.gov/show/NCT00488631,Colitis_Ulcerative,Placebo|Golimumab_50_mg|Golimumab_100_mg|Golimumab_200_mg|,9,659,other_events,arm2,GLM-I-Rsp-Golimumab 100 mg Maintenance,1,154
Dermatitis_Allergic,Skin_and_subcutaneous_tissue_disorders,NCT00488631,https://clinicaltrials.gov/show/NCT00488631,Colitis_Ulcerative,Placebo|Golimumab_50_mg|Golimumab_100_mg|Golimumab_200_mg|,9,659,other_events,arm4,GLM-I-Rsp-Golimumab 50 mg Maintenance-Golimumab 100 mg,1,25
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00489736,https://clinicaltrials.gov/show/NCT00489736,Atrial_Fibrillation,dronedarone_(SR33589)|amiodarone|,1,255,serious_events,arm1,Amiodarone 600mg/200mg od,1,255
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00493285,https://clinicaltrials.gov/show/NCT00493285,Respiratory_Viral_Infections|Respiratory_Syncytial_Virus_Infections|Parainfluenza_Virus_3_Human|,MEDI-534|MEDI-534|MEDI-534|,1,10,other_events,arm4,10^6 MEDI-534,1,10
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00500266,https://clinicaltrials.gov/show/NCT00500266,Pneumococcal_Infections,13-valent_Pneumococcal_Conjugate_Vaccine_(13vPnC),1,1049,other_events,arm0,13vPnC: Visit 1 to Visit 2,1,1049
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00502840,https://clinicaltrials.gov/show/NCT00502840,Rheumatoid_Arthritis,rituximab_[MabThera/Rituxan],3,193,other_events,arm0,Rituximab Plus MTX,3,193
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00507416,https://clinicaltrials.gov/show/NCT00507416,Multiple_Myeloma,Bortezomib|Dexamethasone|Melphalan|Prednisone|Thalidomide|,1,158,other_events,arm1,Bortezomib Thalidomide and Dexamethasone,1,158
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00510952,https://clinicaltrials.gov/show/NCT00510952,Diabetes_Mellitus_Type_2,Insulin_Lispro_Protamine_Suspension|Insulin_Glargine|,4,458,other_events,arm1,Glargine,3,229
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00510952,https://clinicaltrials.gov/show/NCT00510952,Diabetes_Mellitus_Type_2,Insulin_Lispro_Protamine_Suspension|Insulin_Glargine|,4,458,other_events,arm0,Lispro,1,229
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00514813,https://clinicaltrials.gov/show/NCT00514813,Anemia|Kidney_Failure_Chronic|,Dynepo,1,15,other_events,arm0,Dynepo (Epoetin Delta) Twice Weekly (BIW),1,15
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00520494,https://clinicaltrials.gov/show/NCT00520494,Common_Variable_Immunodeficiency|Agammaglobulinemia|,Vivaglobin,1,18,other_events,arm0,Vivaglobin,1,18
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00524459,https://clinicaltrials.gov/show/NCT00524459,Breast_Cancer,docetaxel|pegylated_liposomal_doxorubicin_hydrochloride|conventional_surgery|neoadjuvant_therapy|,1,6,other_events,arm0,DOXIL (Pegylated Liposomal Doxorubicin) and Docetaxel,1,6
DERMATITIS_ALLERGIC,Skin_and_subcutaneous_tissue_disorders,NCT00526474,https://clinicaltrials.gov/show/NCT00526474,Atherosclerosis|Ischemia|Myocardial_Infarction|Cerebrovascular_Accident|Peripheral_Arterial_Disease|,Vorapaxar|Placebo|,2,26352,serious_events,arm1,Vorapaxar,1,13186
DERMATITIS_ALLERGIC,Skin_and_subcutaneous_tissue_disorders,NCT00526474,https://clinicaltrials.gov/show/NCT00526474,Atherosclerosis|Ischemia|Myocardial_Infarction|Cerebrovascular_Accident|Peripheral_Arterial_Disease|,Vorapaxar|Placebo|,2,26352,serious_events,arm0,Placebo,1,13166
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00529529,https://clinicaltrials.gov/show/NCT00529529,Asthma,Indacaterol_300_‘_g|Salmeterol_50_‘_g|Placebo_to_indacaterol|Placebo_to_salmeterol|,1,269,serious_events,arm2,Salmeterol 50 ‘_g,1,269
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00532493,https://clinicaltrials.gov/show/NCT00532493,PTSD|Sleep_Disorders|,prazosin|placebo|,1,152,other_events,arm0,Prazosin Group,1,152
DERMATITIS_ALLERGIC,Skin_and_subcutaneous_tissue_disorders,NCT00538785,https://clinicaltrials.gov/show/NCT00538785,Congenital_Heart_Disease,Motavizumab|Palivizumab|,1,612,serious_events,arm1,Palivizumab,1,612
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00539994,https://clinicaltrials.gov/show/NCT00539994,Infections_Bacterial,retapamulin|Retapamulin|Placebo|,1,15,other_events,arm2,Placebo,1,15
Dermatitis_Allergic,Skin_and_subcutaneous_tissue_disorders,NCT00541658,https://clinicaltrials.gov/show/NCT00541658,Postmenopausal_Osteoporosis,risedronate|risedronate|risedronate|,16,922,other_events,arm2,35 mg Before Breakfast,7,308
Dermatitis_Allergic,Skin_and_subcutaneous_tissue_disorders,NCT00541658,https://clinicaltrials.gov/show/NCT00541658,Postmenopausal_Osteoporosis,risedronate|risedronate|risedronate|,16,922,other_events,arm1,35 mg After Breakfast,5,307
Dermatitis_Allergic,Skin_and_subcutaneous_tissue_disorders,NCT00541658,https://clinicaltrials.gov/show/NCT00541658,Postmenopausal_Osteoporosis,risedronate|risedronate|risedronate|,16,922,other_events,arm0,5 mg Before Breakfast,4,307
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00542386,https://clinicaltrials.gov/show/NCT00542386,Chronic_Kidney_Disease|Dialysis|Hyperphosphatemia|Dyslipidemia|,MCI-196|Placebo|,2,234,other_events,arm3,MCI-196: 12 g,1,102
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00542386,https://clinicaltrials.gov/show/NCT00542386,Chronic_Kidney_Disease|Dialysis|Hyperphosphatemia|Dyslipidemia|,MCI-196|Placebo|,2,234,other_events,arm5,Pooled Placebo,1,132
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00542828,https://clinicaltrials.gov/show/NCT00542828,Myelodysplastic_Syndrome_(MDS),ThymoglobulinŒ¬_Rabbit_Anti-thymocyte_Globulin_(rATG),1,14,other_events,arm0,Thymoglobulin,1,14
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00544557,https://clinicaltrials.gov/show/NCT00544557,Ankylosing_Spondylitis,Etanercept,9,1685,other_events,arm0,Etanercept,9,1685
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00549757,https://clinicaltrials.gov/show/NCT00549757,Type_2_Diabetes_Mellitus|Cardiovascular_Disease|,Aliskiren|Placebo|,1,4272,serious_events,arm0,Core-phase: Aliskiren,1,4272
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00550446,https://clinicaltrials.gov/show/NCT00550446,Arthritis_Rheumatoid,Adalimumab|CP-690-550|CP-690-550|CP-690-550|CP-690550|CP-690550|Placebo|,1,9,other_events,arm7,Adalimumab,1,9
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00553631,https://clinicaltrials.gov/show/NCT00553631,Gaucher_Disease_Type_1,velaglucerase_alfa|imiglucerase|,2,34,serious_events,arm0,Gene-Activated Human Glucocerebrosidase (GA-GCB),1,17
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00553631,https://clinicaltrials.gov/show/NCT00553631,Gaucher_Disease_Type_1,velaglucerase_alfa|imiglucerase|,2,34,other_events,arm0,Gene-Activated Human Glucocerebrosidase (GA-GCB),1,17
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00561353,https://clinicaltrials.gov/show/NCT00561353,Hepatitis_C_Chronic,TMC435|Placebo|Peginterferon_(PegIFN‘±-2a)|Ribavirin|,2,106,other_events,arm0,TMC435 25 mg (Cohort 1/Panel A and B),1,18
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00561353,https://clinicaltrials.gov/show/NCT00561353,Hepatitis_C_Chronic,TMC435|Placebo|Peginterferon_(PegIFN‘±-2a)|Ribavirin|,2,106,other_events,arm10,All TMC435 (All Cohorts),1,88
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00562094,https://clinicaltrials.gov/show/NCT00562094,Erosive_Gastroesophageal_Reflux_Disease|Non-Erosive_Reflux_Disease|,Pantoprazole,1,8616,other_events,arm0,Pantoprazole,1,8616
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00567190,https://clinicaltrials.gov/show/NCT00567190,Metastatic_Breast_Cancer,Pertuzumab|Placebo|Trastuzumab|Docetaxel|,1,407,serious_events,arm0,Pertuzumab + Trastuzumab + Docetaxel,1,407
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00574795,https://clinicaltrials.gov/show/NCT00574795,Vaccines_Pneumococcal_Conjugate_Vaccine,13vPnC,1,185,other_events,arm2,13vPnC Toddler Dose,1,185
DERMATITIS_ALLERGIC,Skin_and_subcutaneous_tissue_disorders,NCT00576823,https://clinicaltrials.gov/show/NCT00576823,Hydronephrosis|Neurogenic_Bladder|,Alfuzosin,1,12,other_events,arm0,Afluzosin Solution - 2-7 Years,1,12
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00581100,https://clinicaltrials.gov/show/NCT00581100,Nail_Psoriasis|Plaque_Psoriasis|,etanercept,2,38,other_events,arm0,Etanercept: Twice Then Once Weekly,2,38
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00607048,https://clinicaltrials.gov/show/NCT00607048,Neoplasms,Paclitaxel_+_Carboplatin_+_CP-870893|Paclitaxel_+_Carboplatin_+_CP-870893|,1,3,other_events,arm0,Schedule A - CP-870893 0.1 mg/kg,1,3
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00607386,https://clinicaltrials.gov/show/NCT00607386,Hunter_Syndrome|Mucopolysaccharidosis_II|MPS_II|,Idursulfase,1,28,other_events,arm0,Idursulfase,1,28
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00607373,https://clinicaltrials.gov/show/NCT00607373,Lipid_Metabolism_Inborn_Errors|Hypercholesterolemia_Autosomal_Dominant|Hyperlipidemias|Metabolic_Diseases|Hyperlipoproteinemia_Type_II|Metabolism_Inborn_Errors|Genetic_Diseases_Inborn|Infant_Newborn_Diseases|Metabolic_Disorder|Congenital_Abnormalities|Hypercholesterolemia|Hyperlipoproteinemias|Dyslipidemias|Lipid_Metabolism_Disorders|,mipomersen|Placebo|,1,34,other_events,arm1,Mipomersen,1,34
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00611455,https://clinicaltrials.gov/show/NCT00611455,Arthritis_Rheumatoid,ofatumumab|Placebo|,5,243,other_events,arm1,Ofatumumab 700 mg: DB and OL Periods,5,243
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00615056,https://clinicaltrials.gov/show/NCT00615056,Colorectal_Neoplasms,Bevacizumab_(avastin)|FOLFIRI_(Irinotecan_leucovorin_5-fluorouracil_[5FU])|AG-013736_(axitinib)|FOLFOX_(oxaliplatin_leucovorin_5-fluorouracil_[5FU])|AG-013736_(axitinib)|FOLFIRI_(irinotecan_leucovorin_5-fluorouracil_[5FU])|Bevacizumab_(avastin)|FOLFOX_(oxaliplatin_leucovorin_5-fluorouracil_[5FU])|,3,117,other_events,arm0,Axitinib + FOLFIRI,1,46
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00615056,https://clinicaltrials.gov/show/NCT00615056,Colorectal_Neoplasms,Bevacizumab_(avastin)|FOLFIRI_(Irinotecan_leucovorin_5-fluorouracil_[5FU])|AG-013736_(axitinib)|FOLFOX_(oxaliplatin_leucovorin_5-fluorouracil_[5FU])|AG-013736_(axitinib)|FOLFIRI_(irinotecan_leucovorin_5-fluorouracil_[5FU])|Bevacizumab_(avastin)|FOLFOX_(oxaliplatin_leucovorin_5-fluorouracil_[5FU])|,3,117,other_events,arm2,Axitinib + FOLFOX,1,36
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00615056,https://clinicaltrials.gov/show/NCT00615056,Colorectal_Neoplasms,Bevacizumab_(avastin)|FOLFIRI_(Irinotecan_leucovorin_5-fluorouracil_[5FU])|AG-013736_(axitinib)|FOLFOX_(oxaliplatin_leucovorin_5-fluorouracil_[5FU])|AG-013736_(axitinib)|FOLFIRI_(irinotecan_leucovorin_5-fluorouracil_[5FU])|Bevacizumab_(avastin)|FOLFOX_(oxaliplatin_leucovorin_5-fluorouracil_[5FU])|,3,117,other_events,arm3,Bevacizumab + FOLFOX,1,35
DERMATITIS_ALLERGIC,Skin_and_subcutaneous_tissue_disorders,NCT00622713,https://clinicaltrials.gov/show/NCT00622713,Alzheimer's_Disease,Rivastigmine_transdermal_patch,1,218,serious_events,arm0,Rivastigmine Transdermal Patch,1,218
Dermatitis_allergic,Immune_system_disorders,NCT00625404,https://clinicaltrials.gov/show/NCT00625404,HIV_Infections,Truvada|Placebo|,51,2058,other_events,arm0,Truvada Arm,30,1025
Dermatitis_allergic,Immune_system_disorders,NCT00625404,https://clinicaltrials.gov/show/NCT00625404,HIV_Infections,Truvada|Placebo|,51,2058,other_events,arm1,Placebo Arm,21,1033
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00631371,https://clinicaltrials.gov/show/NCT00631371,Renal_Cell_Carcinoma,Bevacizumab|Temsirolimus|Bevacizumab|Interferon-Alfa_9MU|,1,393,serious_events,arm0,Bevacizumab+Temsirolimus,1,393
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00632814,https://clinicaltrials.gov/show/NCT00632814,Hemophilia_A,rFVIII-FS_(Kogenate_FS_BAY14-2222)_70_IU/kg_dosing_once_per_week|rFVIII-FS_(Kogenate_FS_BAY14-2222)_70_IU/kg_twice_per_week_(30_IU/kg_+_40_IU/kg)|rFVIII-FS_(Kogenate_FS_BAY14-2222)_75_IU/kg_dosing_three_times_per_week_(3_x_25_IU/kg)|,1,11,other_events,arm0,rFVIII-FS (Kogenate FS BAY14-2222) 70 IU/kg qw,1,11
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00635427,https://clinicaltrials.gov/show/NCT00635427,Gaucher_Disease_Type_1,VPRIVŒ¬,2,38,other_events,arm0,VPRIV 15-60 U/kg (Parent Study VPRIV (15-60 U/kg) TKT034),2,38
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00637377,https://clinicaltrials.gov/show/NCT00637377,Macular_Degeneration,Ranibizumab|Aflibercept_Injection_(EYLEA_VEGF_Trap-Eye_BAY86-5321)|Aflibercept_Injection_(EYLEA_VEGF_Trap-Eye_BAY86-5321)|Aflibercept_Injection_(EYLEA_VEGF_Trap-Eye_BAY86-5321)|,1,307,serious_events,arm3,Aflibercept Injection (EYLEA VEGF Trap-Eye) 2mg Q8,1,307
DERMATITIS_ALLERGIC,Skin_and_subcutaneous_tissue_disorders,NCT00643201,https://clinicaltrials.gov/show/NCT00643201,Venous_Thrombosis,Enoxaparin|warfarin|Placebo_for_apixaban|Placebo_for_enoxaparin|Placebo_for_warfarin|apixaban|,1,2689,serious_events,arm1,Enoxaparin/Warfarin,1,2689
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00656136,https://clinicaltrials.gov/show/NCT00656136,Carcinoma_Non-Small-Cell_Lung,placebo|BIBW_2992|,1,390,serious_events,arm1,Afatinib 50 mg/Day Plus Best Supportive Care (BSC),1,390
Dermatitis_Allergic,Skin_and_subcutaneous_tissue_disorders,NCT00657709,https://clinicaltrials.gov/show/NCT00657709,Serogroup_B_Meningococcal_Meningitis,Serogroup_B_meningococcal_Vaccine_lot_1_(rMenB_Lot_1)|Serogroup_B_meningococcal_Vaccine_lot_2_(rMenB_Lot_2)|Serogroup_B_meningococcal_Vaccine_lot_3_(rMenB_Lot_3)|Infanrix_Hexa|Menjugate|Prevenar|,1,820,serious_events,arm2,rMenB Lot3,1,820
Dermatitis_Allergic,Skin_and_subcutaneous_tissue_disorders,NCT00661479,https://clinicaltrials.gov/show/NCT00661479,Retinitis_Pigmentosa,400_Œµg_Brimonidine_Tartrate_Implant|200_Œµg_Brimonidine_Tartrate_Implant|100_Œµg_Brimonidine_Tartrate_Implant|Sham_(no_implant)|,1,12,other_events,arm0,400 Œµg Brimonidine Tartrate Implant Group B,1,12
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00666224,https://clinicaltrials.gov/show/NCT00666224,Multiple_Sclerosis,Glatiramer_Acetate_(DB)|Placebo|Glatiramer_Acetate_(OL)|,1,454,serious_events,arm2,Glatiramer Acetate (Entire Study),1,454
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00673049,https://clinicaltrials.gov/show/NCT00673049,Carcinoma_Large_Cell|Carcinoma_Non-Small-Cell_Lung|Carcinoma_Squamous_Cell|Carcinoma_Adenosquamous_Cell|,CP_751871_(Figitumumab)|Erlotinib|Erlotinib|,1,290,other_events,arm1,Erlotinib,1,290
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00676091,https://clinicaltrials.gov/show/NCT00676091,Vaccines_Pneumococcal_Conjugate_Vaccine,13-Valent_Pneumococcal_Conjugate_Vaccine_(13vPnC)|7-Valent_Pneumococcal_Conjugate_Vaccine_(7vPnc)|,2,163,other_events,arm0,Infant Series 13vPnC,2,163
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00683800,https://clinicaltrials.gov/show/NCT00683800,Vasomotor_Symptoms,desvenlafaxine_succinate_(DVS)_SR|Placebo|,3,1066,other_events,arm0,DVS SR 100 mg,3,1066
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00686075,https://clinicaltrials.gov/show/NCT00686075,Healthy,MEDI-534_Cohort_1|Placebo_Cohort_1|MEDI-534_Cohort_2|Placebo_Cohort_2|MEDI-534_Cohort_3|Placebo_Cohort_3|MEDI-534_Cohort_4|Placebo_Cohort_4|MEDI-534_Cohort_5|Placebo_Cohort_5|,1,80,other_events,arm3,Placebo Cohort 2,1,80
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00689351,https://clinicaltrials.gov/show/NCT00689351,Pneumococcal_Vaccine,13-valent_pneumococcal_conjugate_vaccine|7-valent_pneumococcal_conjugate_vaccine|,1,89,other_events,arm1,Infant Series 7vPnC,1,89
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00692770,https://clinicaltrials.gov/show/NCT00692770,Carcinoma_Hepatocellular,Nexavar_(Sorafenib_BAY43-9006)|Placebo|,1,559,serious_events,arm0,Sorafenib (Nexavar BAY43-9006),1,559
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00699998,https://clinicaltrials.gov/show/NCT00699998,Acute_Coronary_Syndrome,Clopidogrel|Prasugrel|Commercially-available_Aspirin|,1,4623,serious_events,arm0,Prasugrel,1,4623
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00703326,https://clinicaltrials.gov/show/NCT00703326,Breast_Cancer,ramucirumab_(IMC-1121B)|docetaxel|Placebo|,1,752,serious_events,arm0,Ramucirumab (IMC-1121B) + Docetaxel,1,752
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00708162,https://clinicaltrials.gov/show/NCT00708162,HIV_Infection,Elvitegravir|Raltegravir|Placebo_to_match_elvitegravir|Placebo_to_match_raltegravir|Background_regimen|,1,358,serious_events,arm1,Raltegravir,1,358
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00717522,https://clinicaltrials.gov/show/NCT00717522,Soft_Tissue_Sarcoma,Pomalidomide,1,7,other_events,arm0,Pomalidomide,1,7
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00741338,https://clinicaltrials.gov/show/NCT00741338,Mucopolysaccharidosis_I,Laronidase|Cyclosporine_A_(CsA)|Azathioprine_(Aza)|,1,3,other_events,arm0,Cohort 1,1,3
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00744263,https://clinicaltrials.gov/show/NCT00744263,Pneumonia_Pneumococcal|Pneumococcal_Infections|13-valent_Pneumococcal_Vaccine|,VACCINE:_placebo|VACCINE:_13-valent_pneumococcal_conjugate_vaccine|,2,2011,other_events,arm2,13vPnC Immunogenicity Subset,1,1006
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00744263,https://clinicaltrials.gov/show/NCT00744263,Pneumonia_Pneumococcal|Pneumococcal_Infections|13-valent_Pneumococcal_Vaccine|,VACCINE:_placebo|VACCINE:_13-valent_pneumococcal_conjugate_vaccine|,2,2011,other_events,arm3,Placebo Immunogenicity Subset,1,1005
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00745901,https://clinicaltrials.gov/show/NCT00745901,Contraception,Norgestimate/ethinyl_estradiol;_Drospirenone/ethinyl_estradiol,1,167,other_events,arm0,NGM/25mcg EE,1,167
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00748189,https://clinicaltrials.gov/show/NCT00748189,Leukaemia_Lymphocytic_Chronic,chlorambucil_tablets|ofatumumab_(GSK1841157)_infusion|,1,217,serious_events,arm1,Ofatumumab + Chlorambucil,1,217
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00750880,https://clinicaltrials.gov/show/NCT00750880,Rheumatoid_Arthritis,tocilizumab_[RoActemra/Actemra],1,1681,serious_events,arm0,Tocilizumab 8 mg/kg,1,1681
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00753675,https://clinicaltrials.gov/show/NCT00753675,Biliary_Tract_Cancer|Gallbladder_Cancer|Cancer_Of_The_Extrahepatic_Bile_Duct|Ampullary_Carcinoma|,ZD6474_Vandetanib|ZD6474_Vandetanib|Gemcitabine|Placebo_matching_ZD6474|,2,117,other_events,arm0,Arm A Vandetanib 300 mg,1,59
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00753675,https://clinicaltrials.gov/show/NCT00753675,Biliary_Tract_Cancer|Gallbladder_Cancer|Cancer_Of_The_Extrahepatic_Bile_Duct|Ampullary_Carcinoma|,ZD6474_Vandetanib|ZD6474_Vandetanib|Gemcitabine|Placebo_matching_ZD6474|,2,117,other_events,arm1,Arm B Vandetanib 100mg + Gemcitab,1,58
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00754559,https://clinicaltrials.gov/show/NCT00754559,Rheumatoid_Arthritis,Tocilizumab,1,286,other_events,arm0,Tocilizumab,1,286
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00766675,https://clinicaltrials.gov/show/NCT00766675,Pain|Fibromyalgia|,Tramadol_hydrochloride|Acetaminophen|,1,80,other_events,arm0,Tramadol Hydrochloride/Acetaminophen,1,80
DERMATITIS_ALLERGIC,Skin_and_subcutaneous_tissue_disorders,NCT00781391,https://clinicaltrials.gov/show/NCT00781391,Stroke|Atrial_Fibrillation|Embolism|,warfarin_tablets|Edoxaban_tablets_(high_dose_regimen-60mg)|Edoxaban_tablets_(low_dose_regimen-30mg)|placebo_warfarin|placebo_edoxaban|,3,14014,serious_events,arm1,High Dose Edoxaban/Placebo Warfarin,1,7012
DERMATITIS_ALLERGIC,Skin_and_subcutaneous_tissue_disorders,NCT00781391,https://clinicaltrials.gov/show/NCT00781391,Stroke|Atrial_Fibrillation|Embolism|,warfarin_tablets|Edoxaban_tablets_(high_dose_regimen-60mg)|Edoxaban_tablets_(low_dose_regimen-30mg)|placebo_warfarin|placebo_edoxaban|,3,14014,serious_events,arm2,Low Dose Edoxaban/Placebo Warfarin,2,7002
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00784875,https://clinicaltrials.gov/show/NCT00784875,Primary_Insomnia|Secondary_Insomnia|,LY2624803|LY2624803|Placebo|zolpidem|,2,215,other_events,arm6,Period C - Placebo,1,98
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00784875,https://clinicaltrials.gov/show/NCT00784875,Primary_Insomnia|Secondary_Insomnia|,LY2624803|LY2624803|Placebo|zolpidem|,2,215,other_events,arm2,Period B - Placebo,1,117
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00785577,https://clinicaltrials.gov/show/NCT00785577,Diabetic_Neuropathy_Painful,Placebo|Pregabalin|LY545694_21_mg|LY545694_49_mg|LY545694_105_mg|,1,89,other_events,arm0,Placebo,1,89
Dermatitis_Allergic,Skin_and_subcutaneous_tissue_disorders,NCT00787891,https://clinicaltrials.gov/show/NCT00787891,Gastroesophageal_Reflux_Disease_(GERD),rabeprazole|rabeprazole|,1,33,other_events,arm2,Rabeprazole 0.5 mg/kg (Double-blind Maintenance Phase),1,33
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00791999,https://clinicaltrials.gov/show/NCT00791999,Rheumatoid_Arthritis,CDP870_400mg|CDP870_200mg|CDP870_100mg|Placebo_of_CDP870|,4,154,other_events,arm0,CDP870 100mg,1,72
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00791999,https://clinicaltrials.gov/show/NCT00791999,Rheumatoid_Arthritis,CDP870_400mg|CDP870_200mg|CDP870_100mg|Placebo_of_CDP870|,4,154,other_events,arm1,CDP870 200mg,3,82
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00794664,https://clinicaltrials.gov/show/NCT00794664,Hypercholesterolemia|Coronary_Heart_Disease|,Mipomersen|Placebo|,2,58,other_events,arm1,Mipomersen,1,39
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00794664,https://clinicaltrials.gov/show/NCT00794664,Hypercholesterolemia|Coronary_Heart_Disease|,Mipomersen|Placebo|,2,58,other_events,arm0,Placebo,1,19
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00804986,https://clinicaltrials.gov/show/NCT00804986,Diabetes_Mellitus_Type_2,LY2428757|Placebo|,1,42,other_events,arm2,6.2 mg LY2428757,1,42
Dermatitis_allergic,Infections_and_infestations,NCT00807248,https://clinicaltrials.gov/show/NCT00807248,Major_Depressive_Disorder,Escitalopram_placebo|Gaboxadol_placebo|Escitalopram_20_mg|Gaboxadol_5_mg|Gaboxadol_10_mg|,1,71,other_events,arm0,Placebo (Orally Once Daily),1,71
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00808028,https://clinicaltrials.gov/show/NCT00808028,Meningitis_Meningococcal,meningococcal_B_rLP2086_vaccine.|meningococcal_B_rLP2086_vaccine.|meningococcal_B_rLP2086_vaccine.|normal_saline_(placebo)|,2,316,other_events,arm0,Control- Stage 1,1,121
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00808028,https://clinicaltrials.gov/show/NCT00808028,Meningitis_Meningococcal,meningococcal_B_rLP2086_vaccine.|meningococcal_B_rLP2086_vaccine.|meningococcal_B_rLP2086_vaccine.|normal_saline_(placebo)|,2,316,other_events,arm3,rLP2086 200 mcg- Stage 1,1,195
Dermatitis_Allergic,Skin_and_subcutaneous_tissue_disorders,NCT00809965,https://clinicaltrials.gov/show/NCT00809965,Acute_Coronary_Syndrome|Myocardial_Infarction|Myocardial_Ischemia|Unstable_Angina|,Rivaroxaban_2.5_mg|Rivaroxaban_5_mg|Placebo|Standard_of_care|,2,10225,serious_events,arm1,Rivaroxaban 2.5 mg Bid,1,5115
Dermatitis_Allergic,Skin_and_subcutaneous_tissue_disorders,NCT00809965,https://clinicaltrials.gov/show/NCT00809965,Acute_Coronary_Syndrome|Myocardial_Infarction|Myocardial_Ischemia|Unstable_Angina|,Rivaroxaban_2.5_mg|Rivaroxaban_5_mg|Placebo|Standard_of_care|,2,10225,serious_events,arm2,Rivaroxaban 5 mg Bid,1,5110
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00823719,https://clinicaltrials.gov/show/NCT00823719,Lymphoma_Large-Cell_Diffuse,ofatumumab_+_ICE|ofatumumab_+_DHAP|,2,96,other_events,arm1,Ofatumumab + ICE,1,35
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00823719,https://clinicaltrials.gov/show/NCT00823719,Lymphoma_Large-Cell_Diffuse,ofatumumab_+_ICE|ofatumumab_+_DHAP|,2,96,other_events,arm2,Total Ofatumumab + Chemotherapy,1,61
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00823979,https://clinicaltrials.gov/show/NCT00823979,HIV-1,UK-453061_Dose_1|UK-453061_Dose_2|Etravirine|,2,63,other_events,arm1,Lersivirine 1000 mg,1,32
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00823979,https://clinicaltrials.gov/show/NCT00823979,HIV-1,UK-453061_Dose_1|UK-453061_Dose_2|Etravirine|,2,63,other_events,arm0,Lersivirine 750 mg,1,31
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00824421,https://clinicaltrials.gov/show/NCT00824421,HIV-1,UK-453_061|UK-453_061|EFV_+TVA|,1,63,other_events,arm2,Efavirenz 600 mg,1,63
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00831415,https://clinicaltrials.gov/show/NCT00831415,Major_Depressive_Disorder,desvenlafaxine_succinate_sustained_release_tablets,1,304,other_events,arm0,DVS SR,1,304
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00830960,https://clinicaltrials.gov/show/NCT00830960,Acute_Coronary_Syndrome,Prasugrel|Clopidogrel|,2,135,other_events,arm3,Clopidogrel 300/75 Primary,2,135
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00832091,https://clinicaltrials.gov/show/NCT00832091,Venous_Stasis_Ulcers,Thymosin_Beta_4|Placebo|,1,55,other_events,arm1,Thymosin Beta 4 (T‘_4) at 3 Doses,1,55
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00836875,https://clinicaltrials.gov/show/NCT00836875,Invasive_Aspergillosis,Voriconazole,1,11,other_events,arm0,Voriconazole: 2 to <12 Years,1,11
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00862459,https://clinicaltrials.gov/show/NCT00862459,Brain_Diseases|Spinal_Cord_Diseases|,Gadobutrol~0.03_mmol/kg_BW_(Gadavist_Gadovist_BAY86-4875)|Gadobutrol~0.1_mmol/kg_BW_(Gadavist_Gadovist_BAY86-4875)|Gadobutrol~0.3_mmol/kg_BW_(Gadavist_Gadovist_BAY86-4875)|OptiMARK~0.1_mmol/kg_BW|,1,90,other_events,arm1,Gadobutrol~0.1 mmol/kg BW (Gadavist BAY86-4875),1,90
Dermatitis_Allergic,Skin_and_subcutaneous_tissue_disorders,NCT00864383,https://clinicaltrials.gov/show/NCT00864383,Pulmonary_Tuberculosis,Moxifloxacin_Ethambutol_Isoniazid_Pyrazinamide_&_Rifampicin,5,1930,other_events,arm0,Regimen 1 - 2EHRZ/4HR (Control Regimen),2,639
Dermatitis_Allergic,Skin_and_subcutaneous_tissue_disorders,NCT00864383,https://clinicaltrials.gov/show/NCT00864383,Pulmonary_Tuberculosis,Moxifloxacin_Ethambutol_Isoniazid_Pyrazinamide_&_Rifampicin,5,1930,other_events,arm2,Regimen 3 - 2EMRZ/2MR,2,636
Dermatitis_Allergic,Skin_and_subcutaneous_tissue_disorders,NCT00864383,https://clinicaltrials.gov/show/NCT00864383,Pulmonary_Tuberculosis,Moxifloxacin_Ethambutol_Isoniazid_Pyrazinamide_&_Rifampicin,5,1930,other_events,arm1,Regimen 2 - 2MHRZ/2MHR,1,655
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00865709,https://clinicaltrials.gov/show/NCT00865709,Metastatic_Colorectal_Cancer,Sorafenib_(Nexavar_BAY43-9006)_+_mFOLFOX6_(5-FU_levo-leucovorin_oxaliplatin)|Matching_placebo_+_mFOLFOX6_(5-FU_levo-leucovorin_oxaliplatin)|,2,194,serious_events,arm0,Sorafenib (Nexavar BAY43-9006) + mFOLFOX6,1,97
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00865709,https://clinicaltrials.gov/show/NCT00865709,Metastatic_Colorectal_Cancer,Sorafenib_(Nexavar_BAY43-9006)_+_mFOLFOX6_(5-FU_levo-leucovorin_oxaliplatin)|Matching_placebo_+_mFOLFOX6_(5-FU_levo-leucovorin_oxaliplatin)|,2,194,serious_events,arm2,Sorafenib (Nexavar BAY43-9006) + mFOLFOX6 (OS Update),1,97
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00865904,https://clinicaltrials.gov/show/NCT00865904,Cystic_Fibrosis,VX-809|Placebo|,1,18,other_events,arm1,VX-809 25 mg,1,18
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00868296,https://clinicaltrials.gov/show/NCT00868296,Gastroesophageal_Reflux,pantoprazole,1,46,other_events,arm1,High Dose Pantoprazole,1,46
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00878800,https://clinicaltrials.gov/show/NCT00878800,Dose_Escalation:_Solid_Tumors|MTD:_Soft_Tissue_Sarcomas|,PXD101|Doxorubicin|,1,7,other_events,arm1,Cohort 2: BelDox IV (600/75),1,7
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00880698,https://clinicaltrials.gov/show/NCT00880698,HIV_Infection|Rotavirus_Infection|,RotaTeq|Placebo|,11,138,other_events,arm2,HIV-1 Infected RotaTeq,4,37
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00880698,https://clinicaltrials.gov/show/NCT00880698,HIV_Infection|Rotavirus_Infection|,RotaTeq|Placebo|,11,138,other_events,arm0,HIV-1 Uninfected RotaTeq,1,62
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00880698,https://clinicaltrials.gov/show/NCT00880698,HIV_Infection|Rotavirus_Infection|,RotaTeq|Placebo|,11,138,other_events,arm3,HIV-1 Infected Placebo,6,39
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00895232,https://clinicaltrials.gov/show/NCT00895232,Restless_Legs_Syndrome,Cohort_I|Cohort_II|Cohort_III|,1,6,other_events,arm1,Cohort II (Venofer 500mg X 2 Doses),1,6
DERMATITIS_ALLERGIC,Skin_and_subcutaneous_tissue_disorders,NCT00900627,https://clinicaltrials.gov/show/NCT00900627,Neoplasms|Breast_Neoplasms|Breast_Cancer|,AZD8931|Paclitaxel|Placebo|,1,95,other_events,arm5,Placebo + Paclitaxel,1,95
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00908232,https://clinicaltrials.gov/show/NCT00908232,Multiple_Myeloma,Cyclophosphamide|Bortezomib|Dexamethasone|Lenalidomide|,2,163,other_events,arm0,Complete to Partial Response: Bortezomib + Dexamethasone,1,144
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00908232,https://clinicaltrials.gov/show/NCT00908232,Multiple_Myeloma,Cyclophosphamide|Bortezomib|Dexamethasone|Lenalidomide|,2,163,other_events,arm1,Stable Disease After 4 Cycles: VD VDC VDL,1,19
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00908037,https://clinicaltrials.gov/show/NCT00908037,Purpura_Thrombocytopaenic_Idiopathic,eltrombopag|Placebo|,1,65,other_events,arm3,Part 2/ 3 (Eltrombopag Open-Label Period),1,65
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00911300,https://clinicaltrials.gov/show/NCT00911300,Fibrillation_Atrial,fondaparinux|unfractionated_heparin|Vitamin-K-Antagonist|,1,170,other_events,arm1,UFH/VKA,1,170
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00912925,https://clinicaltrials.gov/show/NCT00912925,Mucopolysaccharidosis_I|Hurlers_Syndrome|Hurler-Scheie_Syndrome|,rhIDU_(recombinant_human-Alpha-L-Iduronidase)|Placebo|,1,23,other_events,arm0,Placebo***Check Title***,1,23
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00918255,https://clinicaltrials.gov/show/NCT00918255,Hidradenitis_Suppurativa,adalimumab|Placebo|,2,51,other_events,arm0,Adalimumab 40 mg Qwk DB,2,51
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00922987,https://clinicaltrials.gov/show/NCT00922987,Neuralgia|Epilepsy|,Lyrica_(pregabalin),1,281,serious_events,arm0,Pregabalin,1,281
DERMATITIS_ALLERGIC,Skin_and_subcutaneous_tissue_disorders,NCT00924443,https://clinicaltrials.gov/show/NCT00924443,Acute_Myeloid_Leukemia,clofarabine,1,66,other_events,arm0,Clofarabine,1,66
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00930176,https://clinicaltrials.gov/show/NCT00930176,Factor_X_Deficiency,Human_Coagulation_FACTOR_X,1,16,other_events,arm0,Human Coagulation FACTOR X,1,16
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00933335,https://clinicaltrials.gov/show/NCT00933335,Lymphoma_Non-Hodgkin|Non-Hodgkin's_Lymphoma|,Tositumomab_and_Iodine_I_131_Tositumomab,2,76,other_events,arm2,Fludarabine/TST and Iodine I 131 TST (Combined Regimen),1,38
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00933335,https://clinicaltrials.gov/show/NCT00933335,Lymphoma_Non-Hodgkin|Non-Hodgkin's_Lymphoma|,Tositumomab_and_Iodine_I_131_Tositumomab,2,76,other_events,arm0,Fludarabine,1,38
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00933270,https://clinicaltrials.gov/show/NCT00933270,Peripheral_Vascular_Disease,SUPERAŒ¬_Nitinol_Stent_System,1,264,serious_events,arm0,SuperaŒ¬ Peripheral Stent System ITT,1,264
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00938015,https://clinicaltrials.gov/show/NCT00938015,Arthritis_Psoriatic,Questionnaire|Questionnaire|,4,301,other_events,arm0,Etanercept,4,301
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00941733,https://clinicaltrials.gov/show/NCT00941733,Critical_Lower_Limb_Ischemia,IN.PACT_Amphirion|Standard_PTA|,1,119,other_events,arm1,Standard PTA,1,119
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00950742,https://clinicaltrials.gov/show/NCT00950742,Breast_Neoplasms,Trastuzumab|BIBW_2992|,1,16,other_events,arm0,Afatinib 20mg + Herceptin,1,16
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00950911,https://clinicaltrials.gov/show/NCT00950911,Bone_Metastases_in_Men_With_Hormone-Refractory_Prostate_Cancer|Bone_Metastases_in_Subjects_With_Advanced_Breast_Cancer|Bone_Metastases_in_Subjects_With_Advanced_Cancer_or_Multiple_Myeloma|,amg_162,1,18,other_events,arm1,Denosumab 120 mg Q4W / Denosumab 120 mg Q4W,1,18
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00975130,https://clinicaltrials.gov/show/NCT00975130,Arthritis_Rheumatoid,SC_golimumab|IV_golimumab|,1,3357,serious_events,arm0,Golimumab 50 mg Subcutaneous (GLM50-SC),1,3357
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00977106,https://clinicaltrials.gov/show/NCT00977106,Rheumatoid_Arthritis,tocilizumab_[RoActemra/Actemra]|placebo|tocilizumab_[RoActemra/Actemra]|,2,100,serious_events,arm1,Placebo Tocilizumab,1,50
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00977106,https://clinicaltrials.gov/show/NCT00977106,Rheumatoid_Arthritis,tocilizumab_[RoActemra/Actemra]|placebo|tocilizumab_[RoActemra/Actemra]|,2,100,other_events,arm1,Placebo Tocilizumab,1,50
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00980798,https://clinicaltrials.gov/show/NCT00980798,Pain|Osteoarthritis_Hip|Osteoarthritis_Knee|,OROS_hydromorphone_HCl|Placebo|,1,149,serious_events,arm0,Placebo,1,149
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00981045,https://clinicaltrials.gov/show/NCT00981045,Iron_Deficiency_Anemia|Impaired_Renal_Function|,Ferric_Carboxymaltose_(FCM)|Iron_Sucrose_(Venofer)|,1,1276,serious_events,arm0,Ferric Carboxymaltose (FCM),1,1276
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00985712,https://clinicaltrials.gov/show/NCT00985712,Diabetes_Mellitus_Type_1,Insulin_Lispro|Huminsulin_Regular|HumaPen_Memoir|HumaPen_Luxura|,1,131,other_events,arm0,HumaPen Luxura,1,131
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00986154,https://clinicaltrials.gov/show/NCT00986154,Venous_Thromboembolism|Deep_Vein_Thrombosis_(DVT)|Pulmonary_Embolism_(PE)|Thromboembolism|Venous_Thrombosis|,edoxaban_tosylate(DU-176b)|low_molecular_weight_heparin/unfractionated_heparin|warfarin|,3,4118,serious_events,arm0,Heparin/Edoxaban Tosylate,3,4118
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT00998296,https://clinicaltrials.gov/show/NCT00998296,Neoplasms,BIBW_2992|BIBF_1120|,1,6,other_events,arm0,Nintedanib 150 mg +Afatinib 30 mg - Continuously,1,6
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT01006629,https://clinicaltrials.gov/show/NCT01006629,Respiratory_Syncytial_Virus_Infection|Premature_Birth|Bronchopulmonary_Dysplasia|Congenital_Heart_Disease|,palivizumab,1,100,other_events,arm0,Palivizumab,1,100
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT01012258,https://clinicaltrials.gov/show/NCT01012258,Squamous_Cell_Carcinoma_of_the_Head_and_Neck,Cetuximab_+_concomitant_boost_radiotherapy,1,66,other_events,arm0,Cetuximab: Treatment Emergent Phase,1,66
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT01015287,https://clinicaltrials.gov/show/NCT01015287,Acute_Coronary_Syndromes,Placebo|Prasugrel|,7,4033,other_events,arm0,Non Pre-treatment,3,1996
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT01015287,https://clinicaltrials.gov/show/NCT01015287,Acute_Coronary_Syndromes,Placebo|Prasugrel|,7,4033,other_events,arm1,Pre-treatment,4,2037
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT01023308,https://clinicaltrials.gov/show/NCT01023308,Multiple_Myeloma,Panobinostat|Bortezomib|,1,377,serious_events,arm1,PBO+BTZ+Dex,1,377
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT01026194,https://clinicaltrials.gov/show/NCT01026194,Type_2_Diabetes_Mellitus,Placebo_/_Teneli_(Teneligliptin)_+_pio_(pioglitazone)|Teneli_/_Teneli_+_pio|,4,206,other_events,arm3,Teneli/Teneli + Pio (Data Through Week 52),2,103
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT01026194,https://clinicaltrials.gov/show/NCT01026194,Type_2_Diabetes_Mellitus,Placebo_/_Teneli_(Teneligliptin)_+_pio_(pioglitazone)|Teneli_/_Teneli_+_pio|,4,206,other_events,arm1,Teneli/Teneli + Pio (Data Through Week 12),2,103
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT01026818,https://clinicaltrials.gov/show/NCT01026818,Erectile_Dysfunction,Tadalafil|Placebo|,1,143,other_events,arm5,Tadalfil 20 mg PRN (Open-Label Period),1,143
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT01035255,https://clinicaltrials.gov/show/NCT01035255,Heart_Failure_With_Reduced_Ejection_Fraction,LCZ696_200_mg_BID|Enalapril_10_mg_BID|,2,4203,serious_events,arm0,LCZ696,2,4203
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT01050634,https://clinicaltrials.gov/show/NCT01050634,Post_Menopausal_Women_With_Early_Breast_Cancer,Aromasin_(exemestane),1,924,other_events,arm0,Observational,1,924
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT01063907,https://clinicaltrials.gov/show/NCT01063907,Multiple_Myeloma,KW-2478|Bortezomib|,2,98,other_events,arm0,Phase 1 and 2: KW-2478 and Bortezomib,1,95
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT01063907,https://clinicaltrials.gov/show/NCT01063907,Multiple_Myeloma,KW-2478|Bortezomib|,2,98,other_events,arm3,Phase 1 Cohort 3: KW-2478 175 mg/m^2 and Bortezomib 1.0 mg/m^2,1,3
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT01065454,https://clinicaltrials.gov/show/NCT01065454,Hypertension_Pulmonary|Ventricular_Dysfunction_Left|,Riociguat_(Adempas_BAY63-2521)|Riociguat_(Adempas_BAY63-2521)|Riociguat_(Adempas_BAY63-2521)|Placebo|,1,33,other_events,arm1,Riociguat (Adempas BAY63-2521) up to 1 mg,1,33
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT01069419,https://clinicaltrials.gov/show/NCT01069419,Rheumatoid_Arthritis,Null,3,1111,serious_events,arm0,Cimzia,3,1111
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT01076959,https://clinicaltrials.gov/show/NCT01076959,Rheumatoid_Arthritis,Null,1,7740,serious_events,arm0,Humira,1,7740
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT01077739,https://clinicaltrials.gov/show/NCT01077739,Colorectal_Cancer,fluorouracil_(5FU)|leucovorin|bevacizumab_[Avastin]|capecitabine_[Xeloda]|oxaliplatin|,1,25,other_events,arm0,Bevacizumab + Oxaliplatin + Capecitabine,1,25
Dermatitis_Allergic,Immune_system_disorders,NCT01078155,https://clinicaltrials.gov/show/NCT01078155,Rheumatoid_Arthritis|Osteoporosis|,Null,1,131,other_events,arm0,Participants With Active Rheumatoid Arthritis (RA),1,131
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT01079182,https://clinicaltrials.gov/show/NCT01079182,Ankylosing_Spondylitis,Null,13,9362,serious_events,arm0,Ankylosing Spondylitis,1,4681
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT01079182,https://clinicaltrials.gov/show/NCT01079182,Ankylosing_Spondylitis,Null,13,9362,other_events,arm0,Ankylosing Spondylitis,12,4681
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT01079962,https://clinicaltrials.gov/show/NCT01079962,Hypertension,Bisoprolol|Atenolol|,1,104,other_events,arm1,Atenolol,1,104
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT01084148,https://clinicaltrials.gov/show/NCT01084148,Uremic_Xerosis,V0034CR01B|V0034CR01B_vehicle|,1,118,other_events,arm0,V0034CR01B,1,118
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT01086384,https://clinicaltrials.gov/show/NCT01086384,Asthma,Fluticasone_Furoate/GW642444|Fluticasone_furoate|,1,1009,serious_events,arm1,FF/VI 100/25 Œµg,1,1009
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT01091519,https://clinicaltrials.gov/show/NCT01091519,Urinary_Bladder_Overactive,Toviaz(fesoterodine)_plus_educational_materials|Toviaz(fesoterodine)_without_educational_materials|,2,431,other_events,arm1,Fesoterodine Without Educational Materials,2,431
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT01099579,https://clinicaltrials.gov/show/NCT01099579,HIV_Infections,Atazanavir_powder|Ritonavir_oral_solution|Atazanavir_capsules|Ritonavir_capsules|,2,37,other_events,arm1,Atazanavir Powder 250 mg/Ritonavir Oral Solution 80 mg,1,16
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT01099579,https://clinicaltrials.gov/show/NCT01099579,HIV_Infections,Atazanavir_powder|Ritonavir_oral_solution|Atazanavir_capsules|Ritonavir_capsules|,2,37,other_events,arm2,Atazanavir Powder 150 mg/Ritonavir Oral Solution 80 mg,1,21
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT01105533,https://clinicaltrials.gov/show/NCT01105533,Neoplasm,PF-00337210|PF-00337210|PF-00337210|PF-00337210|PF-00337210|PF-00337210|PF-00337210|PF-00337210|PF-00337210|PF-00337210|,1,46,other_events,arm0,PF-00337210,1,46
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT01113710,https://clinicaltrials.gov/show/NCT01113710,Idiopathic_Restless_Legs_Syndrome,NeuproŒ¬,14,684,other_events,arm0,NeuproŒ¬,14,684
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT01114880,https://clinicaltrials.gov/show/NCT01114880,Ankylosing_Spondylitis,adalimumab|placebo|,5,566,other_events,arm3,Placebo/Adalimumab (Period 2),1,113
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT01114880,https://clinicaltrials.gov/show/NCT01114880,Ankylosing_Spondylitis,adalimumab|placebo|,5,566,other_events,arm2,Adalimumab/Adalimumab (Period 2),1,224
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT01114880,https://clinicaltrials.gov/show/NCT01114880,Ankylosing_Spondylitis,adalimumab|placebo|,5,566,other_events,arm0,Adalimumab (Period 1),3,229
Dermatitis_allergic,Immune_system_disorders,NCT01120379,https://clinicaltrials.gov/show/NCT01120379,Chronic_Coronary_Occlusion|Vascular_Disease|Myocardial_Ischemia|Coronary_Artery_Stenosis|Coronary_Disease|Coronary_Artery_Disease|Coronary_Restenosis|,XIENCE_VŒ¬_EECSS,1,4852,serious_events,arm0,XV-LTF Cohort,1,4852
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT01126541,https://clinicaltrials.gov/show/NCT01126541,Rheumatoid_Arthritis,rituximab,5,149,other_events,arm1,Randomized Retreatment Arm B: Rituximab 1000 mg x 2,3,68
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT01126541,https://clinicaltrials.gov/show/NCT01126541,Rheumatoid_Arthritis,rituximab,5,149,other_events,arm2,Nonrandomized: Rituximab 1000 mg,2,81
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT01129960,https://clinicaltrials.gov/show/NCT01129960,Painful_Diabetic_Neuropathy,Eslicarbazepine_acetate_(BIA_2-093)|Placebo|,1,83,serious_events,arm1,Esl 1200 mg,1,83
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT01130532,https://clinicaltrials.gov/show/NCT01130532,Erectile_Dysfunction,Tadalafil|Placebo|,1,205,other_events,arm1,5 mg Tadalafil,1,205
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT01140347,https://clinicaltrials.gov/show/NCT01140347,Hepatocellular_Carcinoma,Placebo|Ramucirumab_DP_(IMC-1121B)|BSC|,1,277,serious_events,arm0,Ramucirumab (IMC-1121B) + BSC,1,277
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT01175811,https://clinicaltrials.gov/show/NCT01175811,Diabetes_Mellitus_Type_2,Insulin_Lispro_Premix|Insulin_Glargine|Insulin_Lispro|,1,202,other_events,arm1,Basal-Bolus,1,202
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT01175824,https://clinicaltrials.gov/show/NCT01175824,Diabetes_Mellitus_Type_2,Insulin_Lispro_Low_Mixture_(LM)|Insulin_Glargine|Prandial_Insulin_Lispro|,1,236,other_events,arm0,Insulin Lispro Low Mixture,1,236
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT01179347,https://clinicaltrials.gov/show/NCT01179347,Cystic_Fibrosis,tiotropium_RespimatŒ¬_inhaler|Placebo_RespimatŒ¬_inhaler|,2,455,serious_events,arm3,Tio 5mcg Randomized Group Over the Study,1,308
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT01179347,https://clinicaltrials.gov/show/NCT01179347,Cystic_Fibrosis,tiotropium_RespimatŒ¬_inhaler|Placebo_RespimatŒ¬_inhaler|,2,455,serious_events,arm2,Placebo Randomized Group Over the Openä_ÍLabel Period,1,147
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT01179672,https://clinicaltrials.gov/show/NCT01179672,Diabetic_Neuropathy_Painful,Duloxetine|Placebo|,1,202,other_events,arm0,Duloxetine Treatment,1,202
Dermatitis_Allergic,Skin_and_subcutaneous_tissue_disorders,NCT01193582,https://clinicaltrials.gov/show/NCT01193582,Pneumococcal_Infections,Prevenar|Prevenar|Prevenar|Prevenar|,1,125,other_events,arm2,Group 3,1,125
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT01193335,https://clinicaltrials.gov/show/NCT01193335,13-valent_Pneumococcal_Vaccine|Premature_Birth|Immunization|Safety|,13-valent_pneumococcal_conjugate_vaccine|13-valent_pneumococcal_conjugate_vaccine|,3,200,other_events,arm0,13vPnC Group 1 (Preterm Infant) - Infant Series,2,100
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT01193335,https://clinicaltrials.gov/show/NCT01193335,13-valent_Pneumococcal_Vaccine|Premature_Birth|Immunization|Safety|,13-valent_pneumococcal_conjugate_vaccine|13-valent_pneumococcal_conjugate_vaccine|,3,200,other_events,arm1,13vPnC Group 2 (Term Infant) - Infant Series,1,100
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT01194245,https://clinicaltrials.gov/show/NCT01194245,Diabetes_Mellitus_Type_1,Insulin_lispro|recombinant_human_hyaluronidase_PH20|Insulin_aspart|Insulin_glulisine|Insulin_glargine|,2,117,other_events,arm4,Insulin Lispro (Aspart-PH20 Cohort) Treatment Period,1,59
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT01194245,https://clinicaltrials.gov/show/NCT01194245,Diabetes_Mellitus_Type_1,Insulin_lispro|recombinant_human_hyaluronidase_PH20|Insulin_aspart|Insulin_glulisine|Insulin_glargine|,2,117,other_events,arm3,Aspart-PH20 Treatment Period,1,58
Dermatitis_Allergic,Skin_and_subcutaneous_tissue_disorders,NCT01229176,https://clinicaltrials.gov/show/NCT01229176,Typhoid_Fever,Vi-CRM197_vaccine|Vi_Polysaccharide_(PS)_vaccine|Pneumococcal_conjugate_vaccine|,2,39,other_events,arm7,PNC13 Infants,1,19
Dermatitis_Allergic,Skin_and_subcutaneous_tissue_disorders,NCT01229176,https://clinicaltrials.gov/show/NCT01229176,Typhoid_Fever,Vi-CRM197_vaccine|Vi_Polysaccharide_(PS)_vaccine|Pneumococcal_conjugate_vaccine|,2,39,other_events,arm6,Vi-CRM Infants,1,20
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT01233869,https://clinicaltrials.gov/show/NCT01233869,Polycystic_Kidney_Autosomal_Dominant,Bosutinib|Bosutinib|Placebo|,4,82,other_events,arm0,Bosutinib 200 mg/Day,2,58
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT01233869,https://clinicaltrials.gov/show/NCT01233869,Polycystic_Kidney_Autosomal_Dominant,Bosutinib|Bosutinib|Placebo|,4,82,other_events,arm2,Bosutinib 400/200 mg/Day,2,24
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT01236001,https://clinicaltrials.gov/show/NCT01236001,Seizures,Lacosamide,1,192,other_events,arm0,VimpatŒ¬ Treatment,1,192
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT01236391,https://clinicaltrials.gov/show/NCT01236391,Mantle_Cell_Lymphoma,PCI-32765,1,111,other_events,arm0,PCI-32765,1,111
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT01258660,https://clinicaltrials.gov/show/NCT01258660,Contraception,EE_0.03_mg/DRSP_3_mg/Metafolin_+_folic_acid_placebo|EE_0.03_mg/DRSP_3_mg_(Yasmin)_+_folic_acid|,1,86,other_events,arm0,EE 0.03 mg/DRSP 3 mg/Metafolin + Folic Acid Placebo,1,86
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT01296412,https://clinicaltrials.gov/show/NCT01296412,Diabetes_Mellitus_Type_2,sitagliptin|liraglutide|glimepiride|metformin|,1,324,serious_events,arm1,Liraglutide,1,324
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT01297465,https://clinicaltrials.gov/show/NCT01297465,Assisted_Reproductive_Techniques|Reproductive_Technology_Assisted|,Gonal-fŒ¬|PergoverisŒ¬|PergoverisŒ¬|Recombinant_human_chorionic_gonadotropin_(r-hCG)|,1,103,other_events,arm1,PergoverisŒ¬,1,103
Dermatitis_Allergic,Skin_and_subcutaneous_tissue_disorders,NCT01298531,https://clinicaltrials.gov/show/NCT01298531,Axial_Spondyloarthritis,etanercept|etanercept|placebo|,1,48,other_events,arm1,Placebo to Open Label ETN 50 mg Group,1,48
DERMATITIS_ALLERGIC,Skin_and_subcutaneous_tissue_disorders,NCT01300351,https://clinicaltrials.gov/show/NCT01300351,Breast_Cancer,Fulvestrant|Placebo|,1,109,other_events,arm0,Fulvestrant 500 mg,1,109
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT01301833,https://clinicaltrials.gov/show/NCT01301833,Type_2_Diabetes_Mellitus,Teneli|Teneli_+_Glin|Teneli_+_BG|Teneli_+_A-GI|,2,212,other_events,arm0,Teneli,2,212
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT01302067,https://clinicaltrials.gov/show/NCT01302067,Overactive_Bladder,Fesoterodine_8mg|Fesoterodine_4mg|Placebo|,2,1569,other_events,arm0,Fesoterodine 4 Milligram (mg),1,790
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT01302067,https://clinicaltrials.gov/show/NCT01302067,Overactive_Bladder,Fesoterodine_8mg|Fesoterodine_4mg|Placebo|,2,1569,serious_events,arm2,Fesoterodine 8 mg,1,779
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT01313663,https://clinicaltrials.gov/show/NCT01313663,Lung_Cancer_Small_Cell,pazopanib|pemetrexed|,1,9,other_events,arm0,Pemetrexed 500 mg/m^2,1,9
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT01324128,https://clinicaltrials.gov/show/NCT01324128,Chronic_Kidney_Disease_Requiring_Chronic_Dialysis,PA21_(2.5_g_tablet_containing_500_mg_iron)|Sevelamer_carbonate|PA21-1_(1.25_g_tablet_containing_250_mg_iron)|,1,707,serious_events,arm0,PA21 Stage 1,1,707
Dermatitis_Allergic,Skin_and_subcutaneous_tissue_disorders,NCT01346592,https://clinicaltrials.gov/show/NCT01346592,Influenza_Disease,Trivalent_split_influenza_vaccine_(TIV)|MF59-adjuvanted_trivalent_influenza_vaccine_(aTIV)|Licensed_comparator_trivalent_split_influenza_vaccine_(comparator_TIV)|,1,1474,serious_events,arm2,Comparator TIV (6 to <72 Months),1,1474
DERMATITIS_ALLERGIC,Skin_and_subcutaneous_tissue_disorders,NCT01376700,https://clinicaltrials.gov/show/NCT01376700,Hemophilia_A,Recombinant_antihemophilic_factor_plasma/albumin-free_method_(rAHF-PFM),1,19,other_events,arm0,ADVATE - Prophylactic Regimen,1,19
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT01392378,https://clinicaltrials.gov/show/NCT01392378,Pneumococcal_Vaccines,13-valent_pneumococcal_conjugate_vaccine|INFANRIX_hexa|Paracetamol|13-valent_pneumococcal_conjugate_vaccine|INFANRIX_hexa|Ibuprofen|13-valent_pneumococcal_conjugate_vaccine|INFANRIX_hexa|Paracetamol|13-valent_pneumococcal_conjugate_vaccine|INFANRIX_hexa|Ibuprofen|13-valent_pneumococcal_conjugate_vaccine|INFANRIX_hexa|,10,1252,other_events,arm3,13vPnC+ INFANRIX Hexa+ Ibuprofen Thrice Daily -Infant Series,1,177
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT01392378,https://clinicaltrials.gov/show/NCT01392378,Pneumococcal_Vaccines,13-valent_pneumococcal_conjugate_vaccine|INFANRIX_hexa|Paracetamol|13-valent_pneumococcal_conjugate_vaccine|INFANRIX_hexa|Ibuprofen|13-valent_pneumococcal_conjugate_vaccine|INFANRIX_hexa|Paracetamol|13-valent_pneumococcal_conjugate_vaccine|INFANRIX_hexa|Ibuprofen|13-valent_pneumococcal_conjugate_vaccine|INFANRIX_hexa|,10,1252,other_events,arm2,13vPnC+INFANRIX Hexa+Paracetamol Thrice Daily -Infant Series,1,172
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT01392378,https://clinicaltrials.gov/show/NCT01392378,Pneumococcal_Vaccines,13-valent_pneumococcal_conjugate_vaccine|INFANRIX_hexa|Paracetamol|13-valent_pneumococcal_conjugate_vaccine|INFANRIX_hexa|Ibuprofen|13-valent_pneumococcal_conjugate_vaccine|INFANRIX_hexa|Paracetamol|13-valent_pneumococcal_conjugate_vaccine|INFANRIX_hexa|Ibuprofen|13-valent_pneumococcal_conjugate_vaccine|INFANRIX_hexa|,10,1252,other_events,arm6,13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily -After Inf Ser,1,174
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT01392378,https://clinicaltrials.gov/show/NCT01392378,Pneumococcal_Vaccines,13-valent_pneumococcal_conjugate_vaccine|INFANRIX_hexa|Paracetamol|13-valent_pneumococcal_conjugate_vaccine|INFANRIX_hexa|Ibuprofen|13-valent_pneumococcal_conjugate_vaccine|INFANRIX_hexa|Paracetamol|13-valent_pneumococcal_conjugate_vaccine|INFANRIX_hexa|Ibuprofen|13-valent_pneumococcal_conjugate_vaccine|INFANRIX_hexa|,10,1252,other_events,arm0,13vPnC+ INFANRIX Hexa +Paracetamol Twice Daily -Infant Series,3,173
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT01392378,https://clinicaltrials.gov/show/NCT01392378,Pneumococcal_Vaccines,13-valent_pneumococcal_conjugate_vaccine|INFANRIX_hexa|Paracetamol|13-valent_pneumococcal_conjugate_vaccine|INFANRIX_hexa|Ibuprofen|13-valent_pneumococcal_conjugate_vaccine|INFANRIX_hexa|Paracetamol|13-valent_pneumococcal_conjugate_vaccine|INFANRIX_hexa|Ibuprofen|13-valent_pneumococcal_conjugate_vaccine|INFANRIX_hexa|,10,1252,other_events,arm9,13vPnC + INFANRIX Hexa - After Infant Series,1,210
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT01392378,https://clinicaltrials.gov/show/NCT01392378,Pneumococcal_Vaccines,13-valent_pneumococcal_conjugate_vaccine|INFANRIX_hexa|Paracetamol|13-valent_pneumococcal_conjugate_vaccine|INFANRIX_hexa|Ibuprofen|13-valent_pneumococcal_conjugate_vaccine|INFANRIX_hexa|Paracetamol|13-valent_pneumococcal_conjugate_vaccine|INFANRIX_hexa|Ibuprofen|13-valent_pneumococcal_conjugate_vaccine|INFANRIX_hexa|,10,1252,other_events,arm1,13vPnC + INFANRIX Hexa + Ibuprofen Twice Daily -Infant Series,1,176
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT01392378,https://clinicaltrials.gov/show/NCT01392378,Pneumococcal_Vaccines,13-valent_pneumococcal_conjugate_vaccine|INFANRIX_hexa|Paracetamol|13-valent_pneumococcal_conjugate_vaccine|INFANRIX_hexa|Ibuprofen|13-valent_pneumococcal_conjugate_vaccine|INFANRIX_hexa|Paracetamol|13-valent_pneumococcal_conjugate_vaccine|INFANRIX_hexa|Ibuprofen|13-valent_pneumococcal_conjugate_vaccine|INFANRIX_hexa|,10,1252,other_events,arm12,13vPnC +INFANRIX Hexa +Paracetamol Thrice Daily -Toddler Dose,2,170
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT01413204,https://clinicaltrials.gov/show/NCT01413204,Type_2_Diabetes_Mellitus,TA-7284_Low|TA-7284_High|Placebo|,2,93,other_events,arm2,Placebo,2,93
DERMATITIS_ALLERGIC,Skin_and_subcutaneous_tissue_disorders,NCT01412944,https://clinicaltrials.gov/show/NCT01412944,Plaque-type_Psoriasis,secukinumab_150mg|secukinumab_10mg/kg_i.v._regimen|,1,14,serious_events,arm6,Entire Period: AIN457 150 mg - AIN457 10 mg/kg i.v.,1,14
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT01426789,https://clinicaltrials.gov/show/NCT01426789,Rheumatoid_Arthritis,Placebo|Secukinumab|,1,27,other_events,arm3,Group 3,1,27
DERMATITIS_ALLERGIC,Skin_and_subcutaneous_tissue_disorders,NCT01436643,https://clinicaltrials.gov/show/NCT01436643,Depression|Relapsing-remitting_Multiple_Sclerosis|,Venlafaxine|Fluoxetine|Citalopram|Fingolimod|,1,17,other_events,arm3,Fluoxetine and Fingolimod,1,17
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT01454583,https://clinicaltrials.gov/show/NCT01454583,Arterial_Hypertension,Aliskiren|ACE-I/ARB|No_RAS-inhibition|,1,2696,serious_events,arm1,Group B,1,2696
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT01460342,https://clinicaltrials.gov/show/NCT01460342,Benign_Prostatic_Hyperplasia,Tadalafil|Placebo|,1,304,other_events,arm0,Placebo,1,304
Dermatitis_Allergic,Skin_and_subcutaneous_tissue_disorders,NCT01466062,https://clinicaltrials.gov/show/NCT01466062,Respiratory_Syncytial_Virus_Infection,Palivizumab,1,28,other_events,arm0,Palivizumab,1,28
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT01478373,https://clinicaltrials.gov/show/NCT01478373,Gastrointestinal_Stromal_Tumors,Dovitinib_(TKI258),2,39,other_events,arm0,Dovitinib,2,39
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT01485172,https://clinicaltrials.gov/show/NCT01485172,Parkinson_Disease,ropinirole_monotherapy|placebo_monotherapy|,1,13,other_events,arm1,Treatment Group B: 2 mg/Day,1,13
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT01500720,https://clinicaltrials.gov/show/NCT01500720,Small_Cell_Lung_Cancer,Cabazitaxel|Topotecan|,1,88,serious_events,arm1,Topotecan,1,88
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT01520922,https://clinicaltrials.gov/show/NCT01520922,Leukaemia_Lymphocytic_Chronic,Ofatumumab|Bendamustine|,8,97,other_events,arm1,Ofatumumab + Bendamustine 70 mg/m^2,5,53
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT01520922,https://clinicaltrials.gov/show/NCT01520922,Leukaemia_Lymphocytic_Chronic,Ofatumumab|Bendamustine|,8,97,other_events,arm0,Ofatumumab + Bendamustine 90 mg/m^2,3,44
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT01520909,https://clinicaltrials.gov/show/NCT01520909,Idiopathic_Thrombocytopenic_Purpura,Eltrombopag|Placebo|,3,150,other_events,arm0,Part 1: Eltrombopag,1,63
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT01520909,https://clinicaltrials.gov/show/NCT01520909,Idiopathic_Thrombocytopenic_Purpura,Eltrombopag|Placebo|,3,150,other_events,arm2,Part 2: Eltrombopag,2,87
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT01526785,https://clinicaltrials.gov/show/NCT01526785,Pompe_Disease,Alglucosidase_alfa,1,113,other_events,arm0,Alglucosidase Alfa,1,113
Dermatitis_Allergic,Skin_and_subcutaneous_tissue_disorders,NCT01527513,https://clinicaltrials.gov/show/NCT01527513,Partial_Epilepsy,Eslicarbazepine_acetate_(BIA_2-093)|Placebo|,5,195,other_events,arm2,Part II - ESL,1,112
Dermatitis_Allergic,Skin_and_subcutaneous_tissue_disorders,NCT01527513,https://clinicaltrials.gov/show/NCT01527513,Partial_Epilepsy,Eslicarbazepine_acetate_(BIA_2-093)|Placebo|,5,195,other_events,arm1,Part I - ESL,4,83
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT01544309,https://clinicaltrials.gov/show/NCT01544309,Hypercholesterolemia_With_Concomitant_Type_2_Diabetes,Atorvastatin|Rosuvastatin|,1,506,other_events,arm0,Atorvastatin Administration Group,1,506
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT01555463,https://clinicaltrials.gov/show/NCT01555463,Papulopustular_Rosacea,Azelaic_acid_foam_15_PERCENT_(BAY39-6251)|Vehicle_foam|,1,477,other_events,arm1,Vehicle Foam,1,477
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT01559116,https://clinicaltrials.gov/show/NCT01559116,Pulmonary_Disease_Chronic_Obstructive,tiotropium_+_olodaterol|tiotropium|olodaterol|tiotropium|tiotropium_+_olodaterol|Placebo|Respimat|,1,138,serious_events,arm3,Tiotropium (5 Œµg),1,138
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT01584843,https://clinicaltrials.gov/show/NCT01584843,Strabismus,GSK1358820,1,11,other_events,arm4,GSK1358820 5.0 U,1,11
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT01606254,https://clinicaltrials.gov/show/NCT01606254,Schizophrenia,Paliperidone_palmitate,1,14,other_events,arm2,Paliperidone Palmitate 150 mg,1,14
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT01616459,https://clinicaltrials.gov/show/NCT01616459,Infections_Streptococcal,Pneumococcal_conjugate_vaccine_GSK2830929A|Pneumococcal_conjugate_vaccine_GSK2830930A|Synflorixä‹¢|Prevnar_13ä‹¢|Infanrix_hexaä‹¢|,1,240,serious_events,arm1,12Pn Group,1,240
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT01621191,https://clinicaltrials.gov/show/NCT01621191,Fibromyalgia,Duloxetine,1,149,other_events,arm0,60 mg Duloxetine,1,149
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT01648582,https://clinicaltrials.gov/show/NCT01648582,Type_2_Diabetes_Mellitus,Dulaglutide|Insulin_glargine|Metformin|Sulfonylureas|,1,263,other_events,arm1,0.75 mg Dulaglutide,1,263
DERMATITIS_ALLERGIC,Skin_and_subcutaneous_tissue_disorders,NCT01682876,https://clinicaltrials.gov/show/NCT01682876,Meningococcal_Disease,MenACWY-CRM,2,892,serious_events,arm4,Total,1,713
DERMATITIS_ALLERGIC,Skin_and_subcutaneous_tissue_disorders,NCT01682876,https://clinicaltrials.gov/show/NCT01682876,Meningococcal_Disease,MenACWY-CRM,2,892,serious_events,arm0,2 Through 5 Years (2 Vac),1,179
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT01685216,https://clinicaltrials.gov/show/NCT01685216,Gaucher_Disease_Type_3,velaglucerase_alfa,1,6,other_events,arm0,Velaglucerase Alfa,1,6
Dermatitis_Allergic,Skin_and_subcutaneous_tissue_disorders,NCT01696643,https://clinicaltrials.gov/show/NCT01696643,Opioid-Induced_Constipation,CB-5945|Placebo|,2,1403,other_events,arm0,CB-5945,1,703
Dermatitis_Allergic,Skin_and_subcutaneous_tissue_disorders,NCT01696643,https://clinicaltrials.gov/show/NCT01696643,Opioid-Induced_Constipation,CB-5945|Placebo|,2,1403,other_events,arm1,Placebo,1,700
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT01741792,https://clinicaltrials.gov/show/NCT01741792,Diffuse_Large_B-cell_Lymphoma,Blinatumomab,2,27,other_events,arm4,Blinatumomab Overall,1,25
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT01741792,https://clinicaltrials.gov/show/NCT01741792,Diffuse_Large_B-cell_Lymphoma,Blinatumomab,2,27,other_events,arm1,Cohort 2: Blinatumomab 112 Œµg/d,1,2
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT01807923,https://clinicaltrials.gov/show/NCT01807923,Cystic_Fibrosis_Homozygous_for_the_F508del_CFTR_Mutation,Lumacaftor_Plus_Ivacaftor_Combination|Ivacaftor|Placebo|,2,184,other_events,arm0,Placebo,2,184
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT01808612,https://clinicaltrials.gov/show/NCT01808612,Major_Depressive_Disorder,Fluoxetine|Placebo|,1,83,other_events,arm2,40 mg Fluoxetine (Treatment Period),1,83
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT01857622,https://clinicaltrials.gov/show/NCT01857622,Non-valvular_Atrial_Fibrillation,DU-176b_15mg|DU-176b_30mg|DU-176b_60mg|,1,22,other_events,arm1,Normal/MiRI Low-dose Group,1,22
Dermatitis_Allergic,Skin_and_subcutaneous_tissue_disorders,NCT01964547,https://clinicaltrials.gov/show/NCT01964547,Multiple_Sclerosis|Spasticity|,Sativex|Placebo|,1,62,other_events,arm0,Sativex,1,62
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT01998919,https://clinicaltrials.gov/show/NCT01998919,Non-Small_Cell_Lung_Cancer,erlotinib_[Tarceva]|placebo|gemcitabine|cisplatin|carboplatin|,1,79,other_events,arm0,Placebo Plus Chemotherapy,1,79
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT02314637,https://clinicaltrials.gov/show/NCT02314637,Type_2_Diabetes_Mellitus,Teneligliptin|Teneligliptin_+_Sulfonylurea|,1,151,other_events,arm0,Teneligliptin,1,151
Dermatitis_allergic,Skin_and_subcutaneous_tissue_disorders,NCT02446990,https://clinicaltrials.gov/show/NCT02446990,Coronary_Artery_Disease.,Ivabradine|Placebo|,1,9539,serious_events,arm0,Ivabradine,1,9539